[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 487
1. Giannini PJ, Shetty KV, Horan SL, Reid WD, Litchmore LL: Adenoid cystic carcinoma of the buccal vestibule: A case report and review of the literature. Oral Oncol; 2006 Nov;42(10):1029-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the buccal vestibule: A case report and review of the literature.
  • Minor salivary gland tumors of the buccal vestibule are relatively rare.
  • Adenoid cystic carcinoma is the fifth most common salivary gland malignancy following mucoepidermoid carcinoma, adenocarcinoma not otherwise specified (NOS), acinic cell adenocarcinoma and polymorphous low-grade adenocarcinoma (PLGA).
  • Greater than half of adenoid cystic carcinomas occur in the parotid and submandibular glands.
  • Adenoid cystic carcinoma tends to have a protracted clinical course with wide infiltration and late distant metastases.
  • We present a case of an adenoid cystic carcinoma of the buccal vestibule in a 59-year-old Caucasian female patient that she had been aware of for 15 years.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Mouth Neoplasms / pathology. Salivary Gland Neoplasms / pathology


2. Toida M, Shimokawa K, Makita H, Kato K, Kobayashi A, Kusunoki Y, Hatakeyama D, Fujitsuka H, Yamashita T, Shibata T: Intraoral minor salivary gland tumors: a clinicopathological study of 82 cases. Int J Oral Maxillofac Surg; 2005 Jul;34(5):528-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoral minor salivary gland tumors: a clinicopathological study of 82 cases.
  • We present a retrospective study of 82 patients with intraoral minor salivary gland tumors which were diagnosed from 1979 to 2003 in Gifu University Hospital.
  • A total of 82 tumors, consisting of 55 benign and 27 malignant tumors, were found in 28 male and 54 female Japanese patients; the male-to-female ratio was 1:1.9.
  • The tumors affected the palate (n = 64), the buccal region (n = 10), the upper lip (n = 6), the floor of the mouth (n = 1), and the retromolar region (n = 1).
  • Histologically, the tumors were classified as pleomorphic adenoma (n = 54), papillary cystadenoma (n = 1), adenoid cystic carcinoma (n = 10), mucoepidermoid carcinoma (n = 8), acinic cell carcinoma (n = 3), adenocarcinoma (n = 2), basal cell adenocarcinoma (n = 1), papillary cystadenocarcinoma (n = 1), and carcinoma in pleomorphic adenoma (n = 2).
  • From the results of the present study and review of the literature, it is suggested that the minor salivary gland tumors in Japan may be characterized by a higher incidence of benign tumors, especially of pleomorphic adenoma; a more marked tendency for female predominance; a higher incidence of palatal involvement; and a rarer occurrence of polymorphous low grade adenocarcinoma, in comparison with those reported in the literature from outside of Japan.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenoma, Pleomorphic / epidemiology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / epidemiology. Carcinoma, Mucoepidermoid / epidemiology. Cheek / pathology. Child. Female. Humans. Japan / epidemiology. Lip / pathology. Male. Middle Aged. Palate / pathology. Retrospective Studies. Sex Factors

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16053873.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


3. Goldman NC, Lee J, Tolley B: Acinic cell carcinoma of the parotid gland. Otolaryngol Head Neck Surg; 2007 Nov;137(5):828-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinic cell carcinoma of the parotid gland.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Parotid Neoplasms / pathology

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17967654.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Rembao-Bojórquez D, Vega R, Bermúdez-Maldonado L, Gutiérrez R, Salinas C, Tena-Suck M: Choroid plexus acinar adenoma: a case report. J Neurooncol; 2007 Jun;83(2):191-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroid plexus acinar adenoma: a case report.
  • Mucus-secreting adenomas or acinar adenoma of the choroid plexus are very rare.
  • He was admitted to the hospital with significant tumor expansion and clinical deterioration.
  • Pathological findings were consistent with an acinar choroid plexus adenoma.
  • The tumor was attached to the ependymal lining and was strongly adhered to the walls and floor of the IV ventricle.
  • Post-operative bleeding complicated partial removal of this tumor.
  • [MeSH-major] Adenoma / pathology. Carcinoma, Acinar Cell / pathology. Cerebral Ventricle Neoplasms / pathology. Choroid Plexus Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiographics. 2002 Nov-Dec;22(6):1473-505 [12432118.001]
  • [Cites] Ann Diagn Pathol. 2001 Feb;5(1):43-7 [11172206.001]
  • [Cites] Clin Neuropathol. 1995 May-Jun;14(3):159-61 [7671458.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):230-3 [15551736.001]
  • [Cites] Acta Neuropathol. 1995;89(3):248-57 [7754745.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1980 Sep;43(9):810-7 [6999130.001]
  • [Cites] Surg Neurol. 1982 Apr;17 (4):290-2 [7079955.001]
  • [Cites] Clin Neuropathol. 1991 May-Jun;10(3):137-40 [1860272.001]
  • [Cites] Ultrastruct Pathol. 1999 Sep-Oct;23(5):319-23 [10582269.001]
  • [Cites] Ultrastruct Pathol. 1998 Sep-Oct;22(5):385-91 [9887481.001]
  • [Cites] Neuropediatrics. 1990 Feb;21(1):55-6 [2179761.001]
  • [Cites] J Neurooncol. 2004 May;68(1):49-55 [15174521.001]
  • [Cites] Postgrad Med J. 1999 Feb;75(880):119-20 [10448481.001]
  • [Cites] J Neurosurg. 1970 Nov;33(5):587-90 [5312297.001]
  • [Cites] Neurosurgery. 1999 Feb;44(2):427-8 [9932907.001]
  • [Cites] Brain Tumor Pathol. 2002;19(1):31-4 [12455886.001]
  • [Cites] Laryngoscope. 1997 Feb;107(2):216-21 [9023246.001]
  • [Cites] Acta Cytol. 1996 Mar-Apr;40(2):211-4 [8629400.001]
  • [Cites] Pathol Res Pract. 1996 Aug;192(8):840-4 [8897520.001]
  • [Cites] Laryngoscope. 1993 Dec;103(12):1342-8 [8246652.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):313-25 [15015663.001]
  • [Cites] Neurosurgery. 1998 Jul;43(1):171-3; discussion 173-4 [9657207.001]
  • [Cites] BMC Cancer. 2006 Jun 23;6:165 [16796747.001]
  • [Cites] Acta Neuropathol. 1992;83(6):605-12 [1636378.001]
  • [Cites] Childs Nerv Syst. 2005 May;21(5):410-5 [15565450.001]
  • [Cites] Pediatr Radiol. 2004 Sep;34(9):720-32 [15316692.001]
  • [Cites] Neurosurgery. 1991 Jul;29(1):130-2 [1908063.001]
  • [Cites] Clin Imaging. 2000 May-Jun;24(3):130-1 [11150677.001]
  • (PMID = 17406790.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Mazzullo G, Sfacteria A, Ianelli N, De Majo M, Pennisi MG: Carcinoma of the submandibular salivary glands with multiple metastases in a cat. Vet Clin Pathol; 2005;34(1):61-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the submandibular salivary glands with multiple metastases in a cat.
  • Slides were stained with May-Grünwald Giemsa, and a diagnosis of salivary gland carcinoma was made.
  • At surgery, the tumor was found to involve both submandibular salivary glands as well as adjacent lymph nodes and surrounding tissues.
  • The majority of tissues and organs examined histologically, including mandibular and retropharyngeal lymph nodes, soft palate, laryngopharynx and lungs, contained neoplastic cells whose appearance was consistent with adenocarcinoma.
  • Bilateral salivary adenocarcinoma has not previously been reported in cats, and extensive metastases are rare.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15732021.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Hansel DE, Epstein JI: Sarcomatoid carcinoma of the prostate: a study of 42 cases. Am J Surg Pathol; 2006 Oct;30(10):1316-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid carcinoma of the prostate: a study of 42 cases.
  • Sarcomatoid carcinoma of the prostate is a rare type of prostatic cancer.
  • With the exception of 1 study, the morphologic features and patient outcomes have been reported only in relatively small case series and individual reports.
  • We examined transurethral resection, needle biopsy, and radical prostatectomy specimens from 42 patients with sarcomatoid carcinoma of the prostate, all of which were received in consultation.
  • Prior prostatic adenocarcinoma: The majority of patients (n=21; 66%) had a prior history of acinar adenocarcinoma of the prostate.
  • Of the remaining patients for whom this information was known, 11 patients presented with de novo sarcomatoid carcinoma.
  • The time between the original diagnosis of acinar adenocarcinoma and diagnosis of sarcomatoid carcinoma ranged from 6 months to 16 years (mean 6.8 y).
  • Concurrent adenocarcinoma: The majority of patients demonstrated a concurrent high grade acinar carcinoma of Gleason score 7 (n=3), 8 (n=9), 9 (n=10), and 10 (n=10).
  • A subset of patients contained an admixed ductal adenocarcinoma (n=4), small cell carcinoma (n=3), squamous cell carcinoma (n=3), or other unusual pattern of prostate carcinoma (n=3).
  • In 1 case, the diagnosis was based on immunohistochemical evidence of epithelial differentiation along with the history of prior adenocarcinoma.
  • PROGNOSIS: approximately half of all patients developed metastatic disease either at time of presentation or subsequently.
  • Of patients with meaningful follow-up, 6/7 died within 1 year of the diagnosis of sarcomatoid carcinoma; 20 were alive yet with very short follow-up (median 1 y; mean 2.3 y).
  • Kaplan-Meier analysis revealed that the actuarial risk of death at 1 year after diagnosis of sarcomatoid carcinoma was 20%.
  • No correlation was identified between patient survival and morphologic features, before radiation or hormone therapy, or concurrent high-grade prostate cancer.
  • Sarcomatoid carcinoma demonstrates diverse spindle and epithelial cell morphologies.
  • The epithelial component is typically high-grade acinar adenocarcinoma, yet other aggressive tumor subtypes such as ductal adenocarcinoma and small cell carcinoma may also be seen.
  • Sarcomatoid carcinoma is an aggressive form of prostate cancer, the prognosis of which is dismal regardless of other histologic or clinical findings.
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasms, Multiple Primary. Neoplasms, Second Primary. Prognosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001164.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


7. Wong A, Leong JL, Ho B: Primary acinic cell carcinoma of the ethmoid sinus. Ear Nose Throat J; 2010 Jul;89(7):E40-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary acinic cell carcinoma of the ethmoid sinus.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Ethmoid Sinus / pathology. Ethmoid Sinus / surgery. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Adult. Chronic Disease. Female. Humans. Nasal Obstruction / etiology. Otitis Media, Suppurative / complications

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20628981.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Pickup M, Van der Kwast TH: My approach to intraductal lesions of the prostate gland. J Clin Pathol; 2007 Aug;60(8):856-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By current convention, all high-grade intra-acinar and intraductal neoplastic lesions of prostatic origin fall under the diagnostic umbrella term: prostatic intraepithelial neoplasm (PIN).
  • Illustrating this fact, the well-described ductal subtype of prostatic adenocarcinoma is frequently associated with conventional-type acinar adenocarcinoma, and has a tendency to propagate within adjacent intact prostatic ducts.
  • Clearly, the misdiagnosis of lesions representing invasive disease as preinvasive has the potential for unfavourable clinical sequelae.
  • As yet, however, many of these lesions have escaped the establishment of reliable morphologic criteria or immunohistochemical differentiation for diagnosis.
  • [MeSH-major] Carcinoma, Ductal / pathology. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Biomarkers, Tumor. Carcinoma, Acinar Cell / pathology. Diagnosis, Differential. Humans. Immunohistochemistry / methods. Male. Neoplasm Invasiveness. Prostatic Hyperplasia / pathology. Prostatic Intraepithelial Neoplasia / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Urol Nephrol Suppl. 2000;(205):19-43 [11144897.001]
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1471-9 [10584700.001]
  • [Cites] Semin Urol Oncol. 1999 Nov;17(4):187-98 [10632120.001]
  • [Cites] Prostate. 2000 Sep 1;44(4):265-70 [10951489.001]
  • [Cites] J Clin Pathol. 2000 Sep;53(9):655-65 [11041054.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2000;(205):3-10 [11144902.001]
  • [Cites] Prostate. 1988;12(1):39-46 [2450341.001]
  • [Cites] Am J Surg Pathol. 1988 Aug;12(8):619-33 [2456702.001]
  • [Cites] Semin Diagn Pathol. 1988 Aug;5(3):301-11 [2845546.001]
  • [Cites] Am J Surg Pathol. 1992 Dec;16(12):1205-14 [1281386.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):298-310 [8454275.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):389-95 [11331955.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):794-801 [11395558.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1079-85 [11474294.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):524-34 [11505396.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1161-8 [12218572.001]
  • [Cites] Tumori. 2002 Jul-Aug;88(4):341-4 [12400988.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):303-10 [12604886.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):360-79 [14739906.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5963-72 [15342375.001]
  • [Cites] Prog Urol. 2004 Jun;14(3):411-3 [15373189.001]
  • [Cites] Am J Clin Pathol. 1967 Apr;47(4):497-504 [4164333.001]
  • [Cites] Cancer. 1967 Oct;20(10):1715-22 [4168340.001]
  • [Cites] J Urol. 1971 Dec;106(6):892-902 [5116310.001]
  • [Cites] Cancer. 1976 May;37(5):2255-62 [130969.001]
  • [Cites] J Urol. 1979 Mar;121(3):303-5 [219263.001]
  • [Cites] Cancer. 1985 Oct 1;56(7):1566-73 [4027893.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):111-9 [2416422.001]
  • [Cites] Hum Pathol. 1986 Jan;17(1):64-71 [3943853.001]
  • [Cites] Am J Surg Pathol. 1985 Aug;9(8):595-609 [4091189.001]
  • [Cites] Cancer. 1986 Oct 15;58(8):1714-9 [3756794.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):788-94 [2433020.001]
  • [Cites] Prostate. 1987;10(2):123-31 [2436204.001]
  • [Cites] Am J Surg Pathol. 1995 Jan;19(1):30-6 [7802135.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):2959-62 [7606709.001]
  • [Cites] Am J Surg Pathol. 1995 Aug;19(8):873-86 [7611534.001]
  • [Cites] J Urol. 1995 Nov;154(5):1791-4 [7563348.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):802-14 [8669528.001]
  • [Cites] Cancer. 1996 Jul 15;78(2):330-6 [8674012.001]
  • [Cites] Prostate. 1996 Sep;29(3):137-45 [8827081.001]
  • [Cites] Mod Pathol. 1996 Jul;9(7):742-51 [8832557.001]
  • [Cites] Hum Pathol. 1997 Feb;28(2):143-8 [9023393.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):435-40 [9130990.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1215-22 [9331295.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):703-7 [9477103.001]
  • [Cites] Br J Urol. 1998 Mar;81(3):413-8 [9523662.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):46-9 [9662249.001]
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):840-8 [9669346.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1119-23 [9781651.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):145-52 [9921986.001]
  • [Cites] Eur Urol. 1999;35(5-6):479-83 [10325509.001]
  • [Cites] Am J Surg Pathol. 1999 Jul;23(7):781-5 [10403300.001]
  • [Cites] Am J Surg Pathol. 2000 Jan;24(1):140-4 [10632499.001]
  • [Cites] Hum Pathol. 1999 Dec;30(12):1503-7 [10667430.001]
  • [Cites] Prostate. 2000 Apr 1;43(1):11-9 [10725861.001]
  • [Cites] Am J Surg Pathol. 2000 Aug;24(8):1039-46 [10935644.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):341-6 [15602744.001]
  • [Cites] Virchows Arch. 2005 May;446(5):511-6 [15821929.001]
  • [Cites] Hum Pathol. 2005 May;36(5):531-5 [15948120.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):646-54 [16021571.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):180-5 [16341152.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):820-34 [16469560.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):88-104 [16512601.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):899-906 [16607376.001]
  • [Cites] Neoplasia. 2006 Oct;8(10):826-32 [17032499.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1528-35 [16980940.001]
  • (PMID = 17237185.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 71
  • [Other-IDs] NLM/ PMC1994484
  •  go-up   go-down


9. Zhang S, Bao R, Bagby J, Abreo F: Fine needle aspiration of salivary glands: 5-year experience from a single academic center. Acta Cytol; 2009 Jul-Aug;53(4):375-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 5 false negatives: 2 adenoid cystic carcinomas, 1 acinic cell carcinoma, 1 polymorphous low grade adenocarcinoma and 1 metastatic basaloid squamous cell carcinoma.
  • The only false positive was a pleomorphic adenoma misdiagnosed as adenoid cystic carcinoma.
  • Five benign neoplasms were interpreted as reactive processes, including 2 Warthin's tumors, 2 sebaceous lymphoadenomas and 1 pleomorphic adenoma.
  • The overall accuracy in distinguishing benign from malignant lesions was 79.1%, and the sensitivity for salivary neoplasia was 89.4%.
  • CONCLUSION: Our results are consistent with the literature that salivary gland FNA has good sensitivity, specificity and accuracy in the diagnosis of salivary neoplasms.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697720.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Lee TK, Miller JS, Epstein JI: Rare histological patterns of prostatic ductal adenocarcinoma. Pathology; 2010 Jun;42(4):319-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare histological patterns of prostatic ductal adenocarcinoma.
  • AIMS: Prostatic ductal adenocarcinomas account for 1% of prostate cancers.
  • Most commonly, these lesions grow in large cribriform and/or papillary patterns or, as recently described, in a manner resembling prostatic intraepithelial neoplasia (i.e., 'PIN-like' prostatic ductal adenocarcinoma).
  • This study aims to report rare variants of ductal adenocarcinoma.
  • METHODS: Ten cases of rare patterns of prostatic ductal adenocarcinoma that have not been formally investigated prior to this study, primarily from one author's consultation service (1987-2009), were selected.
  • RESULTS: Two (n = 2) cases were prostatic ductal adenocarcinoma with mucinous and goblet cell features.
  • Three (n = 3) cases are the first described cases of foamy gland prostatic ductal adenocarcinoma.
  • Other unique cases were prostatic duct adenocarcinomas with associated Paneth cell-like neuroendocrine (n = 2), micropapillary (n = 2), and cystic papillary features (n = 1).
  • Four prostatic ductal adenocarcinomas had no evidence of disease at 2-8 years follow-up: foamy gland, Paneth cell-like, and micropapillary (two cases).
  • One mucinous prostatic ductal adenocarcinoma resulted in the patient's death and the other mucinous case was alive at 7 years and 2 months, yet with no information as to status of disease.
  • CONCLUSIONS: In summary, we report several rare and unique histological patterns of prostatic ductal adenocarcinoma.
  • These unusual cases also provide further support for the relationship between acinar and ductal adenocarcinoma.
  • [MeSH-major] Carcinoma, Ductal / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Humans. Male. Middle Aged. Paneth Cells / pathology. Prostatic Intraepithelial Neoplasia / pathology


11. Mizuno Y, Sumi Y, Nachi S, Ito Y, Marui T, Saji S, Matsutomo H: Acinar cell carcinoma arising from an ectopic pancreas. Surg Today; 2007;37(8):704-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma arising from an ectopic pancreas.
  • We herein report a rare case of ectopic pancreatic acinar cell carcinoma (ACC) which presented as a submucosal tumor of the pylorus.
  • Esophago-gastroduodenal endoscopy showed no mucosal lesions, but a submucosal tumor was observed around the pylorus.
  • We diagnosed a gastrointestinal stromal tumor or malignant lymphoma preoperatively, and decided to perform an operation in order to confirm the diagnosis and select the optimal treatment.
  • The resected specimen showed the 7.6 x 4.9-cm size tumor to mainly originate from the pylorus.
  • Histopathologically, the tumor was identified as pancreatic ACC with lymph node metastasis.
  • The tumor cells were labeled by immunohistochemical staining for alpha1-antitrypsin.
  • Because of the tumor location, we considered the tumor to have originated from the ectopic pancreatic tissue in the stomach.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Pancreatic Neoplasms / pathology. Pylorus / pathology. Stomach Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreas. 2001 Apr;22(3):326-9 [11291937.001]
  • [Cites] Arch Pathol Lab Med. 2001 Aug;125(8):1127-8 [11473479.001]
  • [Cites] AJR Am J Roentgenol. 2005 Feb;184(2):511-9 [15671372.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(4):276-9 [15368114.001]
  • [Cites] Pancreas. 2003 Jul;27(1):e18-22 [12826914.001]
  • [Cites] J Comput Assist Tomogr. 2004 Mar-Apr;28(2):180-6 [15091120.001]
  • [Cites] J Surg Oncol. 2004 Jul 15;87(1):53-7 [15221920.001]
  • [Cites] Minerva Gastroenterol Dietol. 1994 Sep;40(3):101-3 [7948318.001]
  • [Cites] Int J Gastrointest Cancer. 2003;34(2-3):67-72 [15361637.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):263-5 [14991547.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3A):1671-4 [16033080.001]
  • [Cites] Pancreas. 2001 Jul;23(1):109-12 [11451140.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • (PMID = 17643220.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Perez EA, Gutierrez JC, Koniaris LG, Neville HL, Thompson WR, Sola JE: Malignant pancreatic tumors: incidence and outcome in 58 pediatric patients. J Pediatr Surg; 2009 Jan;44(1):197-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pancreatic tumors: incidence and outcome in 58 pediatric patients.
  • RESULTS: Malignant pancreatic neoplasms were identified in 58 patients.
  • Tumors were classified as exocrine (n = 31, 53.4%), endocrine (n = 19, 32.8%), or sarcomas (n = 5, 8.6%).
  • Exocrine tumors included pancreatoblastoma (n = 10), solid-cystic tumor (SCT) (n = 10), ductal adenocarcinoma (DA) (n = 7), and acinar cell carcinoma (ACC) (n = 4).
  • Ductal adenocarcinoma, SCT, acinar cell carcinoma, sarcomas, and endocrine tumors were more common in children older than 10 years, whereas pancreatoblastoma was more common in younger children (P = .045).
  • Almost half of patients (n = 25) presented with distant metastasis; of these, 44% were endocrine tumors.
  • There was a significant difference in tumor type 15-year survival with DA having the worst (23%) and SCT the best (100%).

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19159743.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Chetty R, Serra S, Asa SL, Volkan Adsay N: Pancreatic endocrine tumour with ductules: further observations of an unusual histological subtype. Pathology; 2006 Feb;38(1):5-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A study of 21 cases of this variant was undertaken with particular attention paid to the distribution and morphology of the ductules, the presence of entrapped acinar tissue and the surrounding uninvolved pancreatic tissue.
  • However, some cases may have a dominant tubular component, which could present problems at frozen section where the association with fibrosis may invoke a mistaken diagnosis of pancreatic ductal adenocarcinoma or chronic pancreatitis.
  • [MeSH-major] Carcinoma, Islet Cell / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers / analysis. Carcinoma, Pancreatic Ductal / chemistry. Carcinoma, Pancreatic Ductal / pathology. Diagnosis, Differential. Female. Fibrosis / pathology. Humans. Immunohistochemistry. Insulin / analysis. Islets of Langerhans / chemistry. Islets of Langerhans / pathology. Keratins / analysis. Male. Middle Aged. Pancreatitis, Chronic / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484000.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CAM 5.2 antigen; 0 / Insulin; 68238-35-7 / Keratins
  •  go-up   go-down


14. Wang Y, Liu XG, Liang MZ, Qin PX, Lin YJ, Yi XP: [Correlation of early phase contrast enhancement of multi-detector row computed tomography to tumor stroma of nodular solid lung adenocarcinoma]. Ai Zheng; 2008 Nov;27(11):1190-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of early phase contrast enhancement of multi-detector row computed tomography to tumor stroma of nodular solid lung adenocarcinoma].
  • BACKGROUND & OBJECTIVE: Dynamic enhanced multi-detector row CT (MDCT) has been used in differential diagnosis of pulmonary nodules, but its mechanism was unclear yet.
  • This study was to evaluate the correlations of early phase enhancement of MDCT to proportion and distribution of stroma in solid lung adenocarcinoma.
  • METHODS: A total of 31 patients with lung adenocarcinoma underwent routine contrast-enhanced MDCT.
  • Tumor morphology was observed with HE staining.
  • RESULTS: The proportion of invasive stroma in tumors was correlated positively to CT enhancement value (r=0.483, P=0.006).
  • Most acinar adenocarcinomas had net enhancement of > 20 Hu, which was significantly higher than that of solid adenocarcinomas with mucin subtype (P=0.005).
  • CONCLUSIONS: Extent and pattern of CT enhancement of solid lung adenocarcinoma nodules reflect the proliferation and distribution of stroma, respectively.
  • It is helpful to comprehend some false negative on CT enhancement by adequately understanding of the pathologic features of different subtypes of lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radiography. Lung Neoplasms / radiography. Solitary Pulmonary Nodule / radiography. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / radiography. Adult. Aged. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / radiography. Female. Humans. Male. Microvessels / pathology. Microvessels / radiography. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radiographic Image Enhancement

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19000452.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Johnykutty S, Miller CH, Hoda RS, Giampoli EJ: Fine-needle aspiration of dedifferentiated acinic cell carcinoma: Report of a case with cyto-histological correlation. Diagn Cytopathol; 2009 Oct;37(10):763-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration of dedifferentiated acinic cell carcinoma: Report of a case with cyto-histological correlation.
  • Dedifferentiated Acinic Cell Carcinoma (DAcCC) is a rare salivary gland malignancy.
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / surgery. Cell Differentiation. Female. Humans. Lymphatic Metastasis / pathology

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19526576.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Cavallini A, Falconi M, Bortesi L, Crippa S, Barugola G, Butturini G: Pancreatoblastoma in adults: a review of the literature. Pancreatology; 2009;9(1-2):73-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Given the rarity of the disease, the aim of this study was to review our personal experience with adult pancreatoblastoma as well as the cases reported in the literature in order to support clinicians observing this entity.
  • The diagnosis of pancreatoblastoma mainly depends on the pathological findings characterized by squamoid corpuscles at histopathology.
  • Both our patients are disease free after 15 months (case 2) and 51 months (case 1).
  • The latter represents the most successful result in long-term disease-free survival.
  • The differential diagnosis includes nonfunctional pancreatic endocrine tumor, acinar cell carcinoma, solid pseudopapillary tumor and adenocarcinoma.
  • Chemotherapy may play a role as palliative treatment in advanced disease.
  • [MeSH-major] Carcinoma, Neuroendocrine. Pancreatic Neoplasms
  • [MeSH-minor] Adult. Aged. Child. Child, Preschool. Diagnosis, Differential. Humans. Male. Pancreaticoduodenectomy

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel and IAP.
  • (PMID = 19077457.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 36
  •  go-up   go-down


17. Asano T, Seya T, Tanaka N, Ooaki Y, Fujino O: A 13-year-old girl with a preoperatively diagnosed solid cystic tumor of the pancreas. J Nippon Med Sch; 2006 Aug;73(4):231-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 13-year-old girl with a preoperatively diagnosed solid cystic tumor of the pancreas.
  • We report on a 13-year-old girl with a solid cystic tumor of the pancreas.
  • We diagnosed a solid and cystic tumor of the pancreas and subsequently performed distal pancreatectomy.
  • A firm, well-encapsulated tumor was found in the pancreas tail.
  • The cut surface of the tumor consisted of a solid area with hemorrhage and a cystic area.
  • Light microscopy of the tumor confirmed small neoplastic cells.
  • Pathological diagnosis was solid pseudopapillary tumor (solid cystic tumor) of the pancreas.
  • [MeSH-major] Carcinoma, Acinar Cell / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16936450.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Meer S, Altini M: CK7+/CK20- immunoexpression profile is typical of salivary gland neoplasia. Histopathology; 2007 Jul;51(1):26-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumours included pleomorphic adenoma (n = 24), myoepithelioma (n = 9), papillary cystadenoma (n = 3), oncocytoma (n = 2), adenoid cystic carcinoma (n = 22), mucoepidermoid carcinoma (n = 21), polymorphous low-grade adenocarcinoma (n = 21), carcinoma ex-pleomorphic adenoma (n = 11), acinic cell carcinoma (n = 17), epimyoepithelial carcinoma (n = 7), oncocytic carcinoma (n = 3), hyalinizing clear cell carcinoma (n = 1), papillary cystadenocarcinoma (n = 1), salivary duct carcinoma (n = 3), adenocarcinoma (not otherwise specified) (n = 4) and squamous carcinoma (n = 4).
  • Squamous carcinoma showed negative CK7/20 immunoexpression.
  • CONCLUSIONS: Although the CK7/20 immunoprofile is not useful in distinguishing the various types of salivary gland neoplasms or between benign and malignant salivary gland tumours, it may facilitate differentiation of primary salivary gland neoplasia from metastatic tumours and squamous carcinoma, and the diagnosis of metastatic salivary gland tumours.
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Diagnosis, Differential. Gene Expression Regulation, Neoplastic. Humans. Salivary Glands / metabolism. Salivary Glands / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593078.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


19. Mortenson MM, Katz MH, Tamm EP, Bhutani MS, Wang H, Evans DB, Fleming JB: Current diagnosis and management of unusual pancreatic tumors. Am J Surg; 2008 Jul;196(1):100-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current diagnosis and management of unusual pancreatic tumors.
  • BACKGROUND: The finding of a solid or cystic mass in the pancreas is becoming more common secondary to the increasing use of cross-sectional imaging and the improved sensitivity of such studies for the detection of pancreatic abnormalities.
  • This review provides an overview of the natural history, diagnostic considerations, and treatment recommendations for the less common tumors of the pancreas which can be misinterpreted as pancreatic cancer including: solid pseudopapillary tumors (SPT), acinar cell carcinoma (ACC), lymphoplasmacytic sclerosing pancreatitis (LPSP), primary pancreatic lymphoma (PPL), and metastatic renal cell carcinoma to the pancreas.
  • DATA SOURCES: A Medline search was conducted to identify studies investigating the clinicopathologic features, molecular genetics, pathogenesis, diagnosis, and treatment of SPT, ACC, LPSP, PPL, and pancreatic metastases.
  • CONCLUSIONS: It is often possible to obtain an accurate pretreatment diagnosis for these unusual pancreatic tumors and to successfully differentiate them from the more common pancreatic malignancies.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy. Pancreatitis / diagnosis. Pancreatitis / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18466869.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 80
  •  go-up   go-down


20. Furonaka O, Takeshima Y, Awaya H, Kushitani K, Kohno N, Inai K: Aberrant methylation and loss of expression of O-methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma. Pathol Int; 2005 Jun;55(6):303-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant methylation and loss of expression of O-methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma.
  • The methylation status of the MGMT gene was investigated by methylation-specific polymerase chain reaction (PCR) and expression status was investigated by immunohistochemistry in 70 cases of pulmonary squamous cell carcinoma (pulmonary SqCC), including 23 cases of the central type and 47 cases of the peripheral type, and in 53 cases of the peripheral type of pulmonary adenocarcinoma (AC).
  • The frequency of MGMT methylation was 36% in SqCC and 42% in AC.
  • Cases with MGMT methylation correlated significantly with T factor in SqCC (P = 0.047) and AC (P = 0.03).
  • In AC with mixed subtypes showing MGMT methylation, the level of MGMT expression in the bronchioloalveolar carcinoma (BAC) area (non-invasive status) was significantly higher than that in the papillary or acinar AC area (invasive status; P = 0.0002).
  • This trend was not found in AC with mixed subtypes showing no MGMT methylation (P = 0.10).
  • These findings suggest that MGMT inactivation is an event that occurs in the late carcinogenic process in SqCC and AC, and that AC progress from non-invasive status to invasive status with MGMT inactivation induced by the promoter DNA methylation.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. DNA Methylation. Lung Neoplasms / pathology. O(6)-Methylguanine-DNA Methyltransferase / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943786.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


21. Elizalde-Torrent A, Fernández-Cortijo J, San José A: [Acinar cell carcinoma of the lung]. Arch Bronconeumol; 2010 Jun;46(6):340-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinar cell carcinoma of the lung].
  • [Transliterated title] Carcinoma de células acinares de pulmón.
  • [MeSH-major] Carcinoma, Acinar Cell. Lung Neoplasms

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20181420.001).
  • [ISSN] 1579-2129
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  •  go-up   go-down


22. Williams MD, Chakravarti N, Kies MS, Maruya S, Myers JN, Haviland JC, Weber RS, Lotan R, El-Naggar AK: Implications of methylation patterns of cancer genes in salivary gland tumors. Clin Cancer Res; 2006 Dec 15;12(24):7353-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implications of methylation patterns of cancer genes in salivary gland tumors.
  • PURPOSE: We investigated the methylation status and protein expression of four tumor suppressor genes to determine their role in salivary gland tumorigenesis.
  • EXPERIMENTAL DESIGN: We performed methylation-specific PCR and protein analyses of 29 normal salivary glands, 23 benign, and 79 malignant salivary gland neoplasms to determine the pattern and potential diagnostic and/or biological role of the RASSF1, RARbeta2, DAPK, and MGMT tumor suppressor gene methylation in these tumors.
  • Methylation occurred in 9 of 23 (39.1%) benign tumors; 3 (25.0%) pleomorphic adenomas and 6 (66.7%) Warthin's tumors at the MGMT, DAPK, or RASSF1 genes.
  • Methylation occurred in 33 of 79 (41.8%) malignant tumors; 8 (30.8%) adenoid cystic carcinomas, 6 (33.3%) mucoepidermoid carcinomas, 6 (42.9%) acinic cell carcinomas, and 13 (62.0%) salivary duct carcinomas.
  • RASSF1 and RARbeta2 represented 75.8% of methylation events occurring most frequently in salivary duct and acinic cell carcinomas.
  • Overall, we found no significant correlation between protein expression and methylation status of individual genes, but observed low or absent protein expression in several methylated tumors.
  • Significant correlations were found between methylation and aggressive malignant phenotypes (P = 0.0004) and age (P = 0.05).
  • CONCLUSIONS: (a) Benign and malignant salivary tumors differed in the frequency and pattern of gene methylation;.
  • (b) high-grade carcinomas were significantly methylated compared with low-grade phenotypes;.
  • (c) RASSF1 and RARbeta2 were highly methylated in malignant tumors and can be targeted for therapy; and (d) methylation pattern may serve as a diagnostic and biological marker in assessing these tumors.
  • [MeSH-major] Carcinoma / metabolism. DNA Methylation. Salivary Gland Neoplasms / genetics. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Apoptosis Regulatory Proteins / metabolism. Calcium-Calmodulin-Dependent Protein Kinases / metabolism. Carcinoma, Acinar Cell / metabolism. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Mucoepidermoid / metabolism. Child. DNA Modification Methylases. DNA Repair Enzymes. Death-Associated Protein Kinases. Female. Gene Expression Regulation, Neoplastic. Genes, Neoplasm. Humans. Male. Middle Aged. Neoplasm Proteins / metabolism. Receptors, Retinoic Acid / metabolism. Tumor Suppressor Protein p14ARF / metabolism. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17189407.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Neoplasm Proteins; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


23. Thompson LD: Salivary gland acinic cell carcinoma. Ear Nose Throat J; 2010 Nov;89(11):530-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland acinic cell carcinoma.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Salivary Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086276.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Michail P, Karavokyros I, Pikoulis E, Arvelakis A, Charminis G, Michail O, Theodoros D: Acinic cell carcinoma of the parotid gland in children: a case report and literature review. West Indian Med J; 2008 Jan;57(1):70-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinic cell carcinoma of the parotid gland in children: a case report and literature review.
  • Parotid acinic cell carcinoma is a rare malignancy in childhood.
  • Tumour resection revealed acinic cell carcinoma of the parotid gland.
  • The patient has been disease-free for the last five years.
  • We review the literature on acinic cell carcinomas of parotid glands in childhood.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Parotid Neoplasms / pathology

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19565943.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Jamaica
  • [Number-of-references] 26
  •  go-up   go-down


25. Ohike N, Sato M, Hisayuki T, Imataka H, Sato S, Wada Y, Saito K, Takahashi M, Tajiri T, Kunimura T, Morohoshi T: Immunohistochemical analysis of nestin and c-kit and their significance in pancreatic tumors. Pathol Int; 2007 Sep;57(9):589-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of nestin and c-kit and their significance in pancreatic tumors.
  • The purpose of the present study was to clarify the difference of expression of two stem cell markers, nestin and c-kit, among various pancreatic epithelial tumors and evaluate their utility.
  • Immunohistochemistry was done for 99 surgically resected pancreatic tumor specimens, including 20 ductal adenocarcinoma (DAC), two undifferentiated carcinomas (UC), 31 intraductal papillary-mucinous neoplasms (IPMN), six mucinous cystic neoplasms (MCN), five serous cystadenomas (SCA), six acinar cell carcinomas, two pancreatoblastoma (PB), eight solid-pseudopapillary neoplasms (SPN), and 19 endocrine neoplasms (EN).
  • The eight c-kit-positive IPMN included four of 23 adenoma-to-border lesions and four of eight non-invasive-to-invasive carcinomas.
  • The three EN were all carcinomas.
  • These indicate that expression of two stem cell markers is different by tumor type, but the utility of judging direction or degree of differentiation and malignant grade on the basis of their expression status is suggested.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Immunoenzyme Techniques / methods. Intermediate Filament Proteins / analysis. Neoplasm Proteins / metabolism. Nerve Tissue Proteins / analysis. Pancreatic Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17685930.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Nestin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


26. Taraseviciute A, Vincent BT, Schedin P, Jones PL: Quantitative analysis of three-dimensional human mammary epithelial tissue architecture reveals a role for tenascin-C in regulating c-met function. Am J Pathol; 2010 Feb;176(2):827-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To address this question, we focused on tenascin-C (TN-C), a stromal extracellular matrix glycoprotein whose expression increases with disease severity.
  • In the presence of TN-C, however, acini failed to generate a normal BM, and net epithelial cell proliferation increased.
  • To quantify how TN-C alters 3-D tissue architecture and function, we developed a computational image analysis algorithm, which showed that although TN-C disrupted acinar surface structure, it had no effect on their volume.
  • Thus, TN-C promoted epithelial cell proliferation leading to luminal filling, a process that we hypothesized involved c-met, a proto-oncogene amplified in breast tumors that promotes intraluminal filling.
  • Indeed, TN-C increased epithelial c-met expression and promoted luminal filling, whereas blockade of c-met function reversed this phenotype, resulting in normal BM deposition, proper lumen formation, and decreased cell proliferation.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Carcinoma, Ductal / genetics. Carcinoma, Ductal / metabolism. Carcinoma, Ductal / pathology. Cell Culture Techniques. Cell Proliferation. Cell Size. Cells, Cultured. Female. Gene Expression Regulation, Neoplastic. Humans. Imaging, Three-Dimensional. Middle Aged. Models, Biological. Young Adult

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] J Cell Biol. 2003 Apr 28;161(2):393-402 [12741393.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4274-81 [14519655.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):31-40 [14618612.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):753-62 [14644202.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25 [14685170.001]
  • [Cites] J Cell Biol. 2004 Apr 26;165(2):263-73 [15117969.001]
  • [Cites] FASEB J. 2004 Jun;18(9):1016-8 [15059978.001]
  • [Cites] Mol Carcinog. 2004 Dec;41(4):207-20 [15468292.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jan;84(1):136-40 [3467345.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] J Cell Biol. 1989 Oct;109(4 Pt 1):1795-805 [2477381.001]
  • [Cites] J Cell Sci. 1991 Jun;99 ( Pt 2):407-17 [1885677.001]
  • [Cites] J Cell Biol. 1991 Nov;115(4):1127-36 [1720121.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9064-8 [1384042.001]
  • [Cites] J Submicrosc Cytol Pathol. 1993 Apr;25(2):285-95 [7686813.001]
  • [Cites] Mol Biol Cell. 1994 Apr;5(4):439-53 [7519905.001]
  • [Cites] J Cell Sci. 1995 Feb;108 ( Pt 2):413-30 [7768990.001]
  • [Cites] Nature. 1995 Oct 12;377(6549):539-44 [7566154.001]
  • [Cites] Development. 1995 Sep;121(9):2897-908 [7555716.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3509-13 [8622967.001]
  • [Cites] J Cell Biol. 1997 Apr 7;137(1):231-45 [9105051.001]
  • [Cites] Braz J Med Biol Res. 1996 Sep;29(9):1087-97 [9181050.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):301-9 [9221809.001]
  • [Cites] J Cell Biol. 1997 Oct 6;139(1):279-93 [9314546.001]
  • [Cites] Cancer. 1998 Apr 15;82(8):1513-20 [9554529.001]
  • [Cites] Histopathology. 1998 Sep;33(3):275-83 [9777395.001]
  • [Cites] Med Image Anal. 1996 Jun;1(2):91-108 [9873923.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 May;40(6):1071-80 [10235540.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):167-74 [10389993.001]
  • [Cites] Int J Cancer. 2005 Feb 10;113(4):678-82 [15455388.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4324-9 [15738393.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Oct;9(4):343-59 [15838604.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(11):4591-601 [15899862.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):675-88 [16148884.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):241-54 [16169468.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):115-22 [16382120.001]
  • [Cites] Am J Pathol. 2006 Feb;168(2):608-20 [16436674.001]
  • [Cites] J Nucl Med. 2006 Apr;47(4):668-78 [16595502.001]
  • [Cites] Histochem Cell Biol. 2006 Jul;126(1):125-31 [16344911.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3657-60 [16778093.001]
  • [Cites] Genes Dev. 2006 Oct 1;20(19):2673-86 [16983145.001]
  • [Cites] Cancer Lett. 2006 Dec 8;244(2):143-63 [16632194.001]
  • [Cites] Cancer Biol Ther. 2006 Aug;5(8):1002-7 [16775434.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11771-80 [17178873.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Dev Dyn. 2000 Jun;218(2):235-59 [10842355.001]
  • [Cites] Exp Cell Res. 2000 Aug 25;259(1):293-9 [10942601.001]
  • [Cites] Lancet. 2001 Jun 23;357(9273):1992-4 [11438127.001]
  • [Cites] Dev Dyn. 2001 Sep;222(1):115-9 [11507773.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2002 Jan;282(1):L26-35 [11741812.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):46-54 [11900251.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1194-7 [12142372.001]
  • [Cites] Cell. 2002 Oct 4;111(1):29-40 [12372298.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2362-70 [12460779.001]
  • [Cites] Carcinogenesis. 2003 Aug;24(8):1317-23 [12807719.001]
  • (PMID = 20042668.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tenascin; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  • [Other-IDs] NLM/ PMC2808088
  •  go-up   go-down


27. Hansel DE, Nakayama M, Luo J, Abukhdeir AM, Park BH, Bieberich CJ, Hicks JL, Eisenberger M, Nelson WG, Mostwin JL, De Marzo AM: Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate; 2009 May 1;69(6):603-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.
  • BACKGROUND: Small cell carcinoma of the prostate is an uncommon neoplasm, the origin of which has been controversial.
  • To address this, we performed transcriptome profiling and TP53 sequencing of concurrent small cell and prostatic adenocarcinoma to determine the relationship between these entities.
  • METHODS: We identified an unusual case of primary prostate cancer that contained adjacent acinar adenocarcinoma (Gleason score 4 + 3 = 7) and small cell carcinoma.
  • We performed laser capture microdissection to isolate tumor components and performed gene expression and TP53 gene sequence analysis on each component, with results validated by immunohistochemistry for PSA, PSAP, PSMA, androgen receptor, NKX 3.1 and neuroendocrine markers.
  • RESULTS: Transcriptome profiling of the carcinoma components identified 99 genes with a greater than 10-fold differential expression between prostatic adenocarcinoma and small cell carcinoma, many of which have not been previously reported in prostate cancer.
  • The small cell carcinoma component demonstrated upregulation of proliferative and neuroendocrine markers and tyrosine kinase receptors, and downregulation of cell adhesion molecules, supporting the aggressive nature of this form of carcinoma.
  • CONCLUSIONS: This is the first report of a primary small cell carcinoma of the prostate subjected to extensive molecular analysis and the first to show a clonal relation between two morphologically distinct prostate cancer types.
  • The evidence of progression to small cell carcinoma may yield important insights into the pathogenesis of this entity and provide a novel spectrum of molecular markers to further dissect cellular pathways important in tumor progression.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6 [14711987.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):217-27 [14695335.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Aug;5(8):614-25 [15366705.001]
  • [Cites] Cancer. 1987 May 15;59(10):1803-9 [3030528.001]
  • [Cites] Cell. 1992 Jul 24;70(2):293-301 [1638632.001]
  • [Cites] Gastroenterology. 1994 Aug;107(2):420-8 [8039618.001]
  • [Cites] Cancer Res. 1997 Feb 1;57(3):524-31 [9012485.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 15;91(18):1574-80 [10491435.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9209-16 [15604294.001]
  • [Cites] Eur Urol. 2005 Feb;47(2):147-55 [15661408.001]
  • [Cites] FASEB J. 2005 Feb;19(2):243-5 [15548588.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):393-406 [16286247.001]
  • [Cites] J Neurosci. 2005 Nov 16;25(46):10773-85 [16291951.001]
  • [Cites] Am J Surg Pathol. 2006 Jun;30(6):684-93 [16723845.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10683-90 [17108105.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):41-51 [17173048.001]
  • [Cites] Neoplasia. 2007 Feb;9(2):166-80 [17356713.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8460-7 [17875684.001]
  • [Cites] Urol Int. 1999;62(3):133-8 [10529661.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21525-31 [10781613.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4683-8 [11406537.001]
  • [Cites] Blood Cells Mol Dis. 2001 Sep-Oct;27(5):825-9 [11783945.001]
  • [Cites] Prostate. 2002 May 15;51(3):189-200 [11967953.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4499-506 [12154061.001]
  • [Cites] Prostate. 2003 Apr 1;55(1):55-64 [12640661.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2790-9 [15254046.001]
  • (PMID = 19125417.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA058236-10; United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / P50 CA058236; United States / NCI NIH HHS / CA / P50 CA058236-10
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS285484; NLM/ PMC3170854
  •  go-up   go-down


28. Antoine M, Khitrik-Palchuk M, Saif MW: Long-term survival in a patient with acinar cell carcinoma of pancreas. A case report and review of literature. JOP; 2007;8(6):783-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in a patient with acinar cell carcinoma of pancreas. A case report and review of literature.
  • CONTEXT: Acinar cell carcinoma of the pancreas is a rare malignancy that may have acinar and endocrine differentiation.
  • Clinical practice guidelines exist for pancreatic ductal adenocarcinoma.
  • However, treatment protocols for acinar cell carcinoma of the pancreas have not been standardized.
  • CASE REPORT: We describe a case of a 44-year-old woman presenting with low grade fever and mid-abdominal tenderness secondary to a pancreatic mass with acinar and endocrine differentiation metastatic to the liver.
  • The patient developed Clostridium difficile colitis and septic shock resulting in death 37 months after the diagnosis of acinar cell carcinoma of the pancreas.
  • CONCLUSION: This is a case of acinar cell carcinoma of the pancreas with an endocrine component, treated with multiple chemotherapeutic agents, in which the patient survived 37 months after diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Acinar Cell / drug therapy. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17993731.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 28
  •  go-up   go-down


29. Kawakami H, Kuwatani M, Onodera M, Hirano S, Kondo S, Nakanishi Y, Itoh T, Asaka M: Primary acinar cell carcinoma of the ampulla of Vater. J Gastroenterol; 2007 Aug;42(8):694-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary acinar cell carcinoma of the ampulla of Vater.
  • Acinar cell carcinoma of the pancreatobiliary system is a relatively rare malignant neoplasm arising usually in the pancreatic parenchyma.
  • The patient underwent a curative surgical operation, and histopathological examination revealed that the tumor was confined to the ampulla of Vater with no continuity to the pancreatic parenchyma.
  • The tumor cells showed acinar or tubular arrangement with eosinophilic to basophilic granular cytoplasm, findings identical to those of acinar cell carcinoma of the pancreas.
  • Immunohistochemically, the tumor cells were positive for lipase.
  • From these findings, we concluded that the tumor was primary acinar cell carcinoma arising in the ampulla of Vater, probably originating from heterotopic pancreatic tissue.
  • This is the first reported case of primary acinar cell carcinoma in the ampulla of Vater.
  • [MeSH-major] Ampulla of Vater. Carcinoma, Acinar Cell / diagnosis. Common Bile Duct Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Endosonography. Female. Follow-Up Studies. Humans. Middle Aged. Pancreaticoduodenectomy / methods. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2001 Aug;125(8):1127-8 [11473479.001]
  • [Cites] Dig Surg. 2005;22(5):377-9 [16432300.001]
  • [Cites] Arch Pathol Lab Med. 1994 May;118(5):568-71 [8192567.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):263-5 [14991547.001]
  • [Cites] Gastrointest Endosc. 2001 Jan;53(1):121-3 [11154509.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Arch Pathol Lab Med. 1999 Aug;123(8):707-11 [10420228.001]
  • [Cites] Am J Clin Oncol. 1997 Feb;20(1):101-7 [9020300.001]
  • [Cites] Hum Pathol. 2002 Apr;33(4):449-51 [12055683.001]
  • (PMID = 17701134.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


30. Samaratunga H, Delahunt B: Ductal adenocarcinoma of the prostate: current opinion and controversies. Anal Quant Cytol Histol; 2008 Aug;30(4):237-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal adenocarcinoma of the prostate: current opinion and controversies.
  • OBJECTIVE: To evaluate the morphologic spectrum and clinical significance of ductal adenocarcinoma of the prostate (DAP).
  • STUDY DESIGN: We reviewed diagnostic criteria, including the value of immunohistochemistry, and outlined the prognostic implications of a diagnosis of DAP.
  • Immunostaining for prostatic-specific antigen and prostate-specific acid phosphatase is present in these tumors, a high percentage of which overexpress alpha-methylacyl-coenzyme A racemase.
  • A basal cell layer can be seen in some of these tumors, which is probably due to tumor growth into preexisting ducts.
  • This usually represents an advanced stage of tumor progression and is not a precursor of invasive carcinoma.
  • CONCLUSION: DAP are neoplasms of prostatic origin, and the terms endometrioid or endometrial adenocarcinoma are best avoided.
  • The term ductal carcinoma is also inappropriate because this includes some urothelial carcinomas of ductal origin.
  • DAP are aggressive tumors with a shortened average time to progression compared with acinar adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773743.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


31. Seth AK, Argani P, Campbell KA, Cameron JL, Pawlik TM, Schulick RD, Choti MA, Wolfgang CL: Acinar cell carcinoma of the pancreas: an institutional series of resected patients and review of the current literature. J Gastrointest Surg; 2008 Jun;12(6):1061-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas: an institutional series of resected patients and review of the current literature.
  • INTRODUCTION: Acinar cell carcinoma (ACC) is a rare, malignant neoplasm with a generally poor prognosis.
  • MATERIALS AND METHODS: The Johns Hopkins pathology prospective database was reviewed from 1988 to 2006 to identify patients with pancreatic neoplasms possessing features of acinar cell differentiation.
  • Median tumor size was 3.9 cm with 12 patients found to have stage IIB disease or worse.
  • Eight of the fourteen patients developed recurrent disease.
  • Overall median survival and disease-free survival were 33 and 25 months, respectively, as compared to a median survival of 18 months for pancreatic adenocarcinoma.
  • CONCLUSION: Acinar cell carcinomas are rare, aggressive neoplasms that are difficult to diagnose and treat.
  • These lesions have a better prognosis than the more common pancreatic adenocarcinomas.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Pancreatectomy / methods. Pancreatic Neoplasms / pathology. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate / trends. Treatment Outcome. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 1994 Jan;9(1):53-8 [8003821.001]
  • [Cites] Pancreas. 2001 Apr;22(3):326-9 [11291937.001]
  • [Cites] Can Med Assoc J. 1962 Nov 3;87:970-3 [14011794.001]
  • [Cites] AJR Am J Roentgenol. 2005 Feb;184(2):511-9 [15671372.001]
  • [Cites] Br Med J. 1970 Jun 20;2(5711):708-9 [5429656.001]
  • [Cites] Mayo Clin Proc. 1979 Jul;54(7):449-58 [221755.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):739-47 [3542187.001]
  • [Cites] Int Surg. 1984 Oct-Dec;69(4):361-4 [6084650.001]
  • [Cites] J Comput Assist Tomogr. 2004 Mar-Apr;28(2):180-6 [15091120.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Am J Pathol. 1993 Sep;143(3):685-98 [8362971.001]
  • [Cites] J Pathol. 1985 May;146(1):17-29 [2989468.001]
  • [Cites] Int J Gastrointest Cancer. 2003;34(2-3):67-72 [15361637.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] World J Gastroenterol. 2006 May 28;12(20):3180-5 [16718837.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1568-71 [15619219.001]
  • [Cites] Gut. 1990 Aug;31(8):953-5 [2387523.001]
  • [Cites] Ultrastruct Pathol. 2000 Jul-Aug;24(4):227-41 [11013963.001]
  • [Cites] Virchows Arch. 2001 Mar;438(3):312-5 [11315630.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):263-5 [14991547.001]
  • [Cites] Adv Anat Pathol. 2001 May;8(3):144-59 [11345238.001]
  • [Cites] J Clin Pathol. 1977 Feb;30(2):103-12 [845259.001]
  • [Cites] Am J Surg Pathol. 1987 Feb;11(2):85-93 [3812876.001]
  • [Cites] Gastroenterol Jpn. 1992 Dec;27(6):785-91 [1281798.001]
  • [Cites] Acta Cytol. 1996 May-Jun;40(3):585-91 [8669201.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):231-5 [15517367.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):222-5 [10982618.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):938-44 [10987254.001]
  • [Cites] Int J Cancer. 2000 Dec 1;88(5):772-7 [11072247.001]
  • [Cites] Cancer. 1985 Jul 15;56(2):397-402 [4005804.001]
  • [Cites] Cancer. 1974 Apr;33(4):1002-9 [4819206.001]
  • [Cites] Diagn Cytopathol. 1994;10(4):362-4 [7924811.001]
  • [Cites] Gastroenterology. 1965 Nov;49(5):555-9 [5853162.001]
  • [Cites] Cancer Res. 1975 Aug;35(8):2234-48 [167949.001]
  • [Cites] Am J Surg. 2006 Feb;191(2):191-7 [16442944.001]
  • (PMID = 17957440.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Kirkali Z, Montironi R: Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU Int; 2008 Nov;102(10):1369-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare and unusual histological variants of prostatic carcinoma: clinical significance.
  • We review the clinicopathological features of the following unusual histological variants of prostatic carcinoma: small cell carcinoma, ductal adenocarcinoma, sarcomatoid (carcinosarcoma), basal cell, squamous cell and adenosquamous, and urothelial carcinoma.
  • These variants are rare and account for 5-10% of carcinomas that originate in the prostate.
  • Some develop from acinar adenocarcinoma after hormonal or radiation therapy.
  • Only basal cell carcinoma is seen as a low-grade carcinoma.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Acinar Cell / pathology. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Carcinosarcoma / pathology. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18793296.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 56
  •  go-up   go-down


33. Kawakami M, Hirayama A, Tsuchiya K, Ohgawara H, Nakamura M, Umezawa K: Promotion of beta-cell differentiation by the alkaloid conophylline in porcine pancreatic endocrine cells. Biomed Pharmacother; 2010 Mar;64(3):226-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promotion of beta-cell differentiation by the alkaloid conophylline in porcine pancreatic endocrine cells.
  • We previously found that conophylline, an alkaloid isolated from the leaves of Ervatamia microphylla, induced beta-cell differentiation in rat pancreatic acinar carcinoma cells and in cultured fetal rat pancreatic tissue and that it also decreased the blood glucose level in streptozotocin-treated fetal rats.
  • Next we prepared islet-like cell clusters (ICC).
  • Thus, the vinca alkaloid conophylline potentiated beta-cell differentiation in porcine pancreatic endocrine-rich cells in cluster cultures.
  • [MeSH-minor] Animals. Animals, Newborn. Biomarkers. Cell Differentiation / drug effects. Cells, Cultured / drug effects. Drug Evaluation, Preclinical. Drug Synergism. Gene Expression Regulation / drug effects. Glucose / pharmacology. Insulin / secretion. Molecular Structure. Niacinamide / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Sus scrofa. Swine

  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20079600.001).
  • [ISSN] 1950-6007
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Insulin; 0 / Vinca Alkaloids; 0 / conophylline; 25X51I8RD4 / Niacinamide; IY9XDZ35W2 / Glucose
  •  go-up   go-down


34. Minakawa K, Oka K, Nihei T, Sando N, Oikawa H, Toda J, Hosokawa Y, Matsumoto T, Yanagisawa A: Pancreatic endocrine tumor with partial acinar cell differentiation. APMIS; 2006 Oct;114(10):720-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumor with partial acinar cell differentiation.
  • We examined a 70-year-old woman in whom a pancreatic endocrine tumor with partial acinar cell differentiation had been diagnosed.
  • The tumor was located in the pancreatic tail and measured 12.5 x 9.5 x 8 cm.
  • The cells had proliferated in islet-like solid medullary, trabecular, acinar, and papillary patterns.
  • The tumor may be considered an amphicrine tumor.
  • [MeSH-major] Carcinoma, Acinar Cell / diagnosis. Carcinoma, Islet Cell / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pancreas / pathology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Biopsy, Needle. Cytoplasmic Granules / ultrastructure. Female. Humans. Immunohistochemistry. Secretory Vesicles / ultrastructure. Synaptophysin / analysis. Synaptophysin / metabolism. alpha 1-Antitrypsin / analysis. alpha 1-Antitrypsin / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17004975.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Synaptophysin; 0 / alpha 1-Antitrypsin
  •  go-up   go-down


35. Kosmahl M, Pauser U, Anlauf M, Klöppel G: Pancreatic ductal adenocarcinomas with cystic features: neither rare nor uniform. Mod Pathol; 2005 Sep;18(9):1157-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic ductal adenocarcinomas with cystic features: neither rare nor uniform.
  • Cystic tumors of the pancreas are uncommon but important because of their diverse pathology and biology.
  • Their wide spectrum also includes cystic variants of otherwise solid tumors, such as cystic endocrine tumors, cystic acinar cell carcinomas and ductal adenocarcinomas with cystic changes.
  • In this study, we screened pancreatic ductal adenocarcinomas and their variants for macrocystic changes and determined the nature of the cysts (neoplastic vs non-neoplastic).
  • Of 483 tumors 38 (8%) had cystic features.
  • The largest group consisted of 24 pancreatic ductal adenocarcinomas showing a large-gland pattern with small cysts whose diameter varied between 0.5 and 1.8 cm.
  • The second group of cystic tumors (8/483) showed degenerative cystic cavities with diameters ranging between 1 and 6 cm.
  • This group consisted of poorly differentiated pancreatic ductal adenocarcinomas, undifferentiated carcinomas with or without osteoclast-like giant cells and one adenosquamous carcinoma.
  • In the third group of cystic tumors there were four pancreatic ductal adenocarcinomas containing tumor-related retention cysts.
  • The fourth group consisted of two pancreatic ductal adenocarcinomas showing closely attached pseudocysts caused by tumor-associated pancreatitis.
  • The results indicate that a considerable number of pancreatic ductal adenocarcinomas and their variants display cystic features and must therefore be considered in the differential diagnosis of cystic neoplasms of the pancreas.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Cysts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carcinoembryonic Antigen / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mucin 5AC. Mucins / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15920540.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


36. Lakhtakia R, Bharadwaj R, Kumar VK, Mandal P, Nema SK: Immunophenotypic Characterization of Benign and Malignant Prostatic Lesions. Med J Armed Forces India; 2007 Jul;63(3):243-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic Characterization of Benign and Malignant Prostatic Lesions.
  • BACKGROUND: Biopsy diagnosis is the gold standard for differentiating benign and malignant prostatic enlargements.
  • This study was aimed at supplementing biopsy diagnosis with immunophenotypic characters of prostatic lesions.
  • METHODS: Twenty five cases each of nodular hyperplasia and adenocarcinoma prostate were compared for their morphologic appearances and immunophenotyping, by studying antibodies to prostate specific antigen (PSA), transglutaminase, chromogranin and high molecular weight keratin, proliferating cell nuclear antigen, cell death (apoptosis) and neovascularisation (CD 34).
  • PSA negativity avoided metaplasia being overcalled as carcinoma.
  • Loss of basal cells around malignant prostatic acini as determined by high molecular weight keratin (HMWK), was useful in foci of atypical small acinar proliferation and in prostatic intraepithelial neoplasia.
  • Assessment of proliferation indices identified subsets of tumours, within conventional morphologic Gleason's grades, with a higher growth fraction.
  • Cell death determination and study of tumour vessels did not offer any improvement on morphology.
  • CONCLUSION: Immunophenotypic assessment helps in refining morphologic diagnosis of prostatic lesions.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27408008.001).
  • [ISSN] 0377-1237
  • [Journal-full-title] Medical journal, Armed Forces India
  • [ISO-abbreviation] Med J Armed Forces India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC4922757
  • [Keywords] NOTNLM ; Benign / Immunophenotyping / Malignant / Prostate
  •  go-up   go-down


37. Darling MR, Jackson-Boeters L, Daley TD, Diamandis EP: Human kallikrein 6 expression in salivary gland tumors. J Histochem Cytochem; 2006 Mar;54(3):337-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human kallikrein 6 expression in salivary gland tumors.
  • The aim of this study was to determine whether hK6 is expressed in salivary gland tissues and salivary gland tumors (both benign and malignant), using an immunohistochemical method.
  • Pleomorphic adenomas (PA), adenoid cystic carcinomas, polymorphous low-grade adenocarcinomas, acinic cell carcinomas, mucoepidermoid carcinomas, and adenocarcinomas not otherwise specified of both minor and major salivary glands were examined.
  • In all other tumors exhibiting both types of cells, hK6 staining was similar in both duct-like and non-duct-like cells.
  • Tumors that exhibited non-duct-like cells only also exhibited cytoplasmic staining.
  • Results of this study show that salivary gland tumors express hK6, apparently downregulated in comparison with normal salivary gland tissue, and that this expression is not specific for any of the tumors studied.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286664.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.- / KLK6 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


38. Hu YH, Tuo XP, Jin ZD, Liu Y, Guo Y, Luo L: Endoscopic ultrasound (EUS)-guided ethanol injection in hepatic metastatic carcinoma: a case report. Endoscopy; 2010;42 Suppl 2:E256-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound (EUS)-guided ethanol injection in hepatic metastatic carcinoma: a case report.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Endosonography. Ethanol / administration & dosage. Injections, Intra-Arterial / methods. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20931470.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 3K9958V90M / Ethanol
  •  go-up   go-down


39. Scoazec JY: [Case 8: Liver metastasis of pancreatic acinar cell carcinoma]. Ann Pathol; 2007 Apr;27(2):120-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case 8: Liver metastasis of pancreatic acinar cell carcinoma].
  • [MeSH-major] Carcinoma, Acinar Cell / secondary. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909469.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


40. Aokage K, Ishii G, Yoshida J, Hishida T, Nishimura M, Nagai K, Ochiai A: Histological progression of small intrapulmonary metastatic tumor from primary lung adenocarcinoma. Pathol Int; 2010 Dec;60(12):765-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological progression of small intrapulmonary metastatic tumor from primary lung adenocarcinoma.
  • To clarify the morphological features of early metastatic tumor progression, we analyzed the histological heterogeneity of many small intrapulmonary metastases.
  • Histological typing based on the World Health Organization classification (bronchioloalveolar carcinoma, acinar, papillary, and solid subtype) was used to evaluate 234 metastases from the primary lung adenocarcinomas of 139 patients.
  • The predominant subtype of metastasis 3 mm or less in diameter was bronchioloalveolar carcinoma when the primary lesion was diagnosed as predominant bronchioloalveolar carcinoma, acinar, and papillary subtype.
  • When the histology of the primary tumor was predominantly a solid subtype, the predominant subtype of metastatic tumor was also a solid subtype.
  • However, analysis of metastases that were more than 3 mm showed that the predominant subtype of the metastasis reflected the predominant subtype of the primary tumor.
  • Furthermore, we evaluated the number of subtypes in primary and metastatic tumors.
  • These findings suggest that implanted cancer cells display lepidic growth in the early metastatic phase and recapitulate the morphological heterogeneity of the original tumor as the metastasis enlarges.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Neoplasm Metastasis / pathology
  • [MeSH-minor] Aged. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Pathology International © 2010 Japanese Society of Pathology and Blackwell Publishing Asia Pty Ltd.
  • (PMID = 21091834.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


41. Epstein JI: Precursor lesions to prostatic adenocarcinoma. Virchows Arch; 2009 Jan;454(1):1-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor lesions to prostatic adenocarcinoma.
  • High-grade prostatic intraepithelial neoplasia (PIN) is the one well-documented precursor to adenocarcinoma of the prostate.
  • Benign lesions that may be confused with high-grade PIN, including central zone histology, clear cell cribriform hyperplasia, and basal cell hyperplasia are described and illustrated.
  • High-grade PIN is also differentiated from invasive acinar (usual) and ductal adenocarcinoma.
  • The incidence of high-grade PIN, its relationship to carcinoma (including molecular findings), and risk of cancer on rebiopsy are covered in detail.
  • Finally, intraductal carcinoma of the prostate, a controversial entity, is discussed and differentiated from high-grade PIN.
  • [MeSH-major] Adenocarcinoma / pathology. Precancerous Conditions / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / pathology. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Intraepithelial Neoplasia / pathology. Risk Factors

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):840-8 [9669346.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):882-8 [17527075.001]
  • [Cites] J Clin Pathol. 2006 Apr;59(4):437-9 [16567473.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):929-33; discussion 933 [16469583.001]
  • [Cites] Urology. 1995 Dec;46(6):837-42 [7502426.001]
  • [Cites] Urology. 1997 Apr;49(4):558-63 [9111625.001]
  • [Cites] Eur Urol. 1999;35(5-6):474-8 [10325508.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12):1534-9 [11717544.001]
  • [Cites] J Urol. 2006 Jan;175(1):121-4 [16406886.001]
  • [Cites] BJU Int. 2003 Mar;91(4):350-4 [12603413.001]
  • [Cites] Am J Surg Pathol. 2000 Jan;24(1):140-4 [10632499.001]
  • [Cites] Urology. 2004 Mar;63(3):503-8 [15028446.001]
  • [Cites] Int J Cancer. 1997 Dec 10;73(6):808-11 [9399656.001]
  • [Cites] BJU Int. 2007 Apr;99(4):765-9 [17378840.001]
  • [Cites] Hum Pathol. 1991 Jul;22(7):644-52 [1712748.001]
  • [Cites] Am J Surg Pathol. 1989 May;13(5):389-96 [2469333.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2118-24 [2004331.001]
  • [Cites] Hum Pathol. 2006 Mar;37(3):292-7 [16613324.001]
  • [Cites] Prostate. 2000 Apr 1;43(1):11-9 [10725861.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2008;11(1):20-31 [17909565.001]
  • [Cites] Hum Pathol. 2002 May;33(5):518-23 [12094377.001]
  • [Cites] Am J Surg Pathol. 1985 Aug;9(8):595-609 [4091189.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):629-33 [15105651.001]
  • [Cites] Cancer. 1969 Jan;23(1):24-34 [5763258.001]
  • [Cites] In Vivo. 1994 May-Jun;8(3):439-43 [7803731.001]
  • [Cites] Urology. 2006 Oct;68(4):800-3 [17070356.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):111-9 [2416422.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):645-59 [7686348.001]
  • [Cites] Urology. 2007 Dec;70(6):1100-3 [18158026.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1291-6 [11283929.001]
  • [Cites] Mod Pathol. 1996 Jul;9(7):742-51 [8832557.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):788-94 [2433020.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):389-91 [9458077.001]
  • [Cites] J Urol. 2000 Mar;163(3):819-23 [10687984.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):794-801 [11395558.001]
  • [Cites] Am J Surg Pathol. 1995 Aug;19(8):873-86 [7611534.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1170-81 [15498784.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1184-8 [16931964.001]
  • [Cites] Eur Urol. 2005 Sep;48(3):379-85 [15961218.001]
  • [Cites] Prostate. 2000 Sep 1;44(4):265-70 [10951489.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):298-310 [8454275.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):389-95 [11331955.001]
  • [Cites] Am J Surg Pathol. 1986 Oct;10(10):665-71 [3766845.001]
  • [Cites] Cancer Lett. 1999 Jul 1;141(1-2):173-8 [10454259.001]
  • [Cites] Am J Surg Pathol. 2008 Jul;32(7):1060-7 [18496142.001]
  • [Cites] J Urol. 1997 Jul;158(1):12-22 [9186314.001]
  • [Cites] Hum Pathol. 2005 May;36(5):480-5 [15948114.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):802-14 [8669528.001]
  • [Cites] BJU Int. 2007 Apr;99(4):770-4 [17233800.001]
  • [Cites] BJU Int. 2004 Sep;94(4):528-33 [15329106.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1415-8 [12352407.001]
  • [Cites] Urology. 2005 Apr;65(4):745-9 [15833520.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1215-22 [9331295.001]
  • [Cites] Urology. 1997 Sep;50(3):355-9 [9301697.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):1008-13 [15297968.001]
  • [Cites] Hum Pathol. 1986 Jan;17(1):64-71 [3943853.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):435-40 [9130990.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):899-906 [16607376.001]
  • [Cites] Cancer. 1986 Oct 15;58(8):1714-9 [3756794.001]
  • [Cites] Urology. 2001 Dec;58(6):999-1003 [11744476.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 1):379-85 [8326560.001]
  • [Cites] J Urol. 2008 May;179(5):1751-5; discussion 1755 [18343427.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2617-22 [18451224.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):967-71 [10487854.001]
  • [Cites] Int J Oncol. 2005 Jan;26(1):267-74 [15586249.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1528-35 [16980940.001]
  • [Cites] J Urol. 2001 May;165(5):1409-14 [11342887.001]
  • [Cites] Prostate. 1996 Aug;29(2):117-34 [8700801.001]
  • [Cites] Neoplasia. 2006 Oct;8(10 ):826-32 [17032499.001]
  • [Cites] Am J Surg Pathol. 1992 Dec;16(12):1205-14 [1281386.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1079-85 [11474294.001]
  • [Cites] Int Urol Nephrol. 2007;39(1):189-95 [16835725.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):275-89 [15323145.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3966-71 [8508361.001]
  • [Cites] J Urol. 2005 Oct;174(4 Pt 1):1390-4; discussion 1394; author reply 1394 [16145444.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):820-34 [16469560.001]
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):147-55 [11176063.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):360-79 [14739906.001]
  • [Cites] Can J Urol. 2006 Oct;13(5):3255-60 [17076947.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1119-23 [9781651.001]
  • [Cites] J Urol. 1995 Oct;154(4):1295-9 [7544835.001]
  • (PMID = 19048290.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 85
  •  go-up   go-down


42. Yamaue H: [Clinical characteristics of invasive ductal carcinomas of the pancreas according to the histological differentiation]. Nihon Rinsho; 2006 Jan;64 Suppl 1:48-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics of invasive ductal carcinomas of the pancreas according to the histological differentiation].
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Carcinoma / epidemiology. Carcinoma / pathology. Carcinoma, Acinar Cell / epidemiology. Carcinoma, Acinar Cell / pathology. Humans. Neoplasm Invasiveness / pathology. Prognosis. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16457220.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 14
  •  go-up   go-down


43. Chang F, Chandra A, Culora G, Mahadeva U, Meenan J, Herbert A: Cytologic diagnosis of pancreatic endocrine tumors by endoscopic ultrasound-guided fine-needle aspiration: a review. Diagn Cytopathol; 2006 Sep;34(9):649-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic diagnosis of pancreatic endocrine tumors by endoscopic ultrasound-guided fine-needle aspiration: a review.
  • Precise localization and diagnosis of pancreatic endocrine tumors (PETs) is important, because pancreatic PETs have different clinical and biological behavior and treatment modalities than do exocrine pancreatic tumors.
  • In contrast to the much more common exocrine adenocarcinomas, cytologic studies of PET are relatively rare and many cytopathologists lack experience with the cytomorphologic features of these tumors.During the last 10 yr, endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNA) has matured into an accurate, highly sensitive, and cost-effective modality for the preoperative localization of pancreatic PETs.
  • This manuscript focuses on the cytomorphologic features most suggestive of pancreatic PETs, differential diagnosis, and diagnostic pitfalls of PETs.
  • The data summarized in this review indicate that EUS-FNA is a valuable method in the recognition of pancreatic PETs and in most cases cytopathologists could reach a correct diagnosis of these tumors, including their hormone producing capability on aspirated cytologic material.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Carcinoma, Islet Cell / pathology. Endoscopy, Digestive System / methods. Insulinoma / pathology. Pancreatic Neoplasms / pathology. Ultrasonography / methods
  • [MeSH-minor] Adenocarcinoma, Papillary / pathology. Biomarkers, Tumor / analysis. Carcinoma, Acinar Cell / pathology. Carcinoma, Pancreatic Ductal / pathology. Diagnosis, Differential. Gastrinoma / chemistry. Gastrinoma / pathology. Glucagonoma / chemistry. Glucagonoma / pathology. Humans. Immunohistochemistry. Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16900463.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 74
  •  go-up   go-down


44. Sanati S, Watson MA, Salavaggione AL, Humphrey PA: Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate. Mod Pathol; 2009 Oct;22(10):1273-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate.
  • Ductal adenocarcinoma is an uncommon variant of prostatic adenocarcinoma with a generally more aggressive clinical course than usual acinar adenocarcinoma.
  • However, the molecular distinction between ductal and acinar adenocarcinomas is not well characterized.
  • The aim of this investigation was to evaluate the relatedness of ductal versus acinar prostatic adenocarcinoma by comparative gene expression profiling.
  • Archived, de-identified, snap frozen tumor tissue from 5 ductal adenocarcinomas, 3 mixed ductal-acinar adenocarcinomas, and 11 acinar adenocarcinomas cases were analyzed.
  • All cases of acinar and ductal adenocarcinomas were matched by Gleason grade.
  • RNA from whole tissue sections of the 5 ductal and 11 acinar adenocarcinomas cases were subjected to gene expression profiling on Affymetrix U133Plus2 microarrays.
  • Independently, laser-capture microdissection was also performed on the three mixed ductal-acinar cases and five pure acinar cases to isolate homogeneous populations of ductal and acinar carcinoma cells from the same tumor.
  • Seven of these laser-capture microdissected samples (three ductal and four acinar cell populations) were similarly analyzed on U133Plus2 arrays.
  • Analysis of data from whole sections of ductal and acinar carcinomas identified only 25 gene transcripts whose expression was significantly and at least two-fold different between ductal and acinar adenocarcinomas.
  • A similar analysis of microdissected cell populations identified 10 transcripts, including the prolactin receptor, with more significant differences in expression of 5- to 27-fold between ductal and acinar adenocarcinomas cells.
  • Overexpression of prolactin receptor protein in ductal versus acinar adenocarcinoma was confirmed by immunohistochemistry in an independent set of tumors.
  • We conclude that ductal and acinar adenocarcinomas of the prostate are strikingly similar at the level of gene expression.
  • However, several of the genes identified in this study, including the prolactin receptor, represent targets for further investigations on the molecular basis for histomorphological and clinical behavioral differences between acinar and ductal adenocarcinomas.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Acinar Cell / genetics. Carcinoma, Ductal / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19633648.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Prolactin
  •  go-up   go-down


45. Diegel CR, Cho KR, El-Naggar AK, Williams BO, Lindvall C: Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma. Cancer Res; 2010 Nov 15;70(22):9143-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma.
  • Cross-talk between the canonical Wnt and mammalian target of rapamycin (mTOR) signaling pathways occurs at multiple levels in the cell and likely contributes to the oncogenic effects of these pathways in human cancer.
  • To gain more insight into the interplay between Wnt and mTOR signaling in salivary gland tumorigenesis, we developed a mouse model in which both pathways are constitutively activated by the conditional inactivation of the Apc and Pten tumor suppressor genes.
  • Loss of either Apc or Pten alone did not cause tumor development.
  • However, deletion of both genes resulted in the formation of salivary gland tumors with 100% penetrance and short latency that showed a remarkable morphologic similarity to human acinic cell carcinoma.
  • Treatment of tumor-bearing mice using the mTOR inhibitor rapamycin led to complete regression of tumors, indicating that tumor growth was dependent on continued mTOR signaling.
  • Importantly, we found that human salivary gland acinic cell carcinomas also express markers of activated mTOR signaling.
  • Together, these results suggest that aberrant activation of mTOR signaling plays a pivotal role in acinar cell neoplasia of the salivary gland.
  • Because rapamycin analogues are approved for treating other types of human malignancies, our findings suggest that rapamycin therapy should be evaluated for treating patients with salivary gland acinic cell carcinoma.
  • [MeSH-major] Adenomatous Polyposis Coli Protein / deficiency. Carcinoma, Acinar Cell / metabolism. PTEN Phosphohydrolase / deficiency. Salivary Glands / metabolism. TOR Serine-Threonine Kinases / metabolism
  • [MeSH-minor] Animals. Antibiotics, Antineoplastic / pharmacology. Apoptosis / drug effects. Female. Flow Cytometry. Humans. Immunohistochemistry. Male. Mice. Mice, 129 Strain. Mice, Knockout. Salivary Gland Neoplasms / genetics. Salivary Gland Neoplasms / metabolism. Salivary Gland Neoplasms / pathology. Signal Transduction / drug effects. Sirolimus / pharmacology. Tumor Burden / drug effects


46. Omlie JE, Koutlas IG: Acinic cell carcinoma of minor salivary glands: a clinicopathologic study of 21 cases. J Oral Maxillofac Surg; 2010 Sep;68(9):2053-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinic cell carcinoma of minor salivary glands: a clinicopathologic study of 21 cases.
  • PURPOSE: Acinic cell carcinoma (ACC) is an infrequent type of malignant salivary gland tumor.
  • This study was undertaken to 1) report on the clinicopathologic characteristics of 21 intraoral examples, 2) reconfirm the reported indolent behavior of these tumors, and 3) verify the synchronous or metachronous occurrence of other malignancies with ACC.
  • The size of the tumors varied from 0.6 to 1.6 cm.
  • Eleven patients did not report recurrence or metastatic disease.
  • One patient had 2 recurrences due to erroneous diagnosis that led to inappropriate treatment.
  • After properly diagnosed and treated, this patient has been free of tumor for 4 years.
  • Of interest were the metachronous occurrence of lymphoma in 1 patient and the synchronous occurrence of renal cell carcinoma in another.
  • CONCLUSION: This study confirms the indolent behavior of ACC of minor salivary glands and previous reports on the occasional synchronous or metachronous association of malignant salivary gland tumors with other malignancies.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Neoplasms, Multiple Primary. Neoplasms, Second Primary. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Renal Cell / parasitology. Female. Humans. Kidney Neoplasms / pathology. Lymph Nodes / pathology. Lymphoma / pathology. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20576339.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Lakhani A, Maas L: Necrotizing panniculitis: a skin condition associated with acinar cell carcinoma of the pancreas. South Med J; 2008 May;101(5):554-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Necrotizing panniculitis: a skin condition associated with acinar cell carcinoma of the pancreas.
  • Pancreatic panniculitis (PP) is a rare cutaneous eruption that is associated with severe pancreatic disease.
  • Thorough investigation revealed stage IV acinar cell carcinoma of the pancreas.
  • Panniculitis should be kept in mind in the differential diagnosis of inflamed appearing nodules and pustules with an erythematous base, particularly when they are progressive and unrelenting.
  • [MeSH-major] Carcinoma, Acinar Cell / complications. Pancreatic Neoplasms / complications. Panniculitis / etiology
  • [MeSH-minor] Amylases / blood. Cellulitis / diagnosis. Diagnosis, Differential. Exanthema / etiology. Humans. Lipase / blood. Male. Middle Aged. Necrosis

  • Genetic Alliance. consumer health - Panniculitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414166.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.1.1.3 / Lipase; EC 3.2.1.- / Amylases
  •  go-up   go-down


48. Bryan JN, Keeler MR, Henry CJ, Bryan ME, Hahn AW, Caldwell CW: A population study of neutering status as a risk factor for canine prostate cancer. Prostate; 2007 Aug 1;67(11):1174-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Veterinary Medical Databases (VMDB) were queried to yield male dogs with urinary bladder transitional cell carcinoma (TCC), prostate adenocarcinoma (ACA), prostate TCC, prostate carcinoma (CA), and prostate tumors.
  • A second query yielded all male dogs over the age of 4 years without a diagnosis of urinary tract cancer.
  • These populations were compared to determine relative risks for developing each disease, singly and collectively, associated with neutering status.
  • Neutered males had an odds ratio of 3.56 (3.02-4.21) for urinary bladder TCC, 8.00 (5.60-11.42) for prostate TCC, 2.12 (1.80-2.49) for prostate adenocarcinoma, 3.86 (3.13-4.16) for prostate carcinoma, and 2.84 (2.57-3.14) for all prostate cancers.
  • Relative risks were highly similar when cases were limited to those with a histologically confirmed diagnosis.
  • The risk associated with being neutered is highest for TCC, supporting previous work identifying the urothelium and ductular rather than acinar epithelium as the source of these tumors.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / veterinary. Animals. Carcinoma / epidemiology. Carcinoma / veterinary. Carcinoma, Transitional Cell / epidemiology. Carcinoma, Transitional Cell / veterinary. Dogs. Genetic Predisposition to Disease. Male. Odds Ratio. Risk Factors. Species Specificity. Urinary Bladder Neoplasms / epidemiology. Urinary Bladder Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17516571.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Grant] United States / NLM NIH HHS / LM / T15-LM07089
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


49. Tavora F, Epstein JI: High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases. Am J Surg Pathol; 2008 Jul;32(7):1060-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
  • Most of the prostatic ductal adenocarcinomas of the prostate are characterized by cribriform and/or papillary architecture lined by columnar pseudostratified malignant epithelium.
  • We report 28 cases of ductal adenocarcinomas on needle biopsy and transurethral resection of prostate closely resembling high-grade prostatic intraepithelial neoplasia (HGPIN) composed of simple glands with flat, tufting, or micropapillary architecture.
  • Prostate specific antigen serum level at diagnosis ranged from 1.2 to 12.1 ng/mL.
  • Three patients had recent biopsies without information on treatment and 3 patients were lost to follow-up after diagnosis.
  • The number of cores involved by tumor in each case ranged from 1 to 18, with more than 1 core involved in 13 cases.
  • In radical prostatectomies, tumor was primarily composed of small (25%), medium (17%), or cystically dilated (58%) cancer glands, with all cases demonstrating a mixture of different gland sizes.
  • Cytologically, tumors were characterized by tall columnar atypical cells, basally located nuclei, and amphophilic cytoplasm.
  • The tumors lacked marked pleomorphism, necrosis, solid areas, cribriform formation, or true papillary fronds.
  • In the radical prostatectomy specimens, tumor volumes ranged from a small focus (less than 0.01 cm3) to 1.2 cm3.
  • Concurrent conventional acinar Gleason score 6 adenocarcinomas were seen in 6 of the 9 radical prostatectomy cases, in all cases as separate nodules from the PIN-like ductal adenocarcinomas.
  • Only one of the PIN-like ductal adenocarcinomas at radical prostatectomy had extraprostatic extension, which was focal.
  • PIN-like ductal adenocarcinoma differs from HGPIN by the presence of cystically dilated glands, a greater predominance of flat architecture, and less frequently prominent nucleoli.
  • Although usual ductal adenocarcinoma is considered comparable to Gleason score 8, PIN-like ductal adenocarcinoma was accompanied by Gleason score 6 acinar carcinoma and behaved similar to Gleason score 6 acinar cancer.
  • Recognition of this entity is critical to differentiate it from both HGPIN and conventional ductal adenocarcinoma.
  • [MeSH-major] Carcinoma, Ductal / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Biomarkers, Tumor / analysis. Biopsy, Needle. Cryotherapy. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Prostatectomy. Radiotherapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18496142.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


50. Yildirim N, Oksüzoğlu B, Vural M, Han O, Zengin N: Case report: cavernous sinus metastasis of the parotid carcinoma: a very unusual case. J Neurooncol; 2005 Jun;73(2):181-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: cavernous sinus metastasis of the parotid carcinoma: a very unusual case.
  • Cavernous sinus is an uncommon site of metastasis for the head and neck tumors, and especially for the tumors of parotid gland.
  • The case reported here is the second reported case of parotid carcinoma metastatic to the cavernous sinus, proven by histopathology.
  • Also it is the first reported parotid gland acinic cell carcinoma metastasis to the cavernous sinus.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Acinar Cell / secondary. Cavernous Sinus / pathology. Parotid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 1990 Sep-Oct;12(5):426-9 [2211104.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Nov;125(5):567-8 [11700465.001]
  • [Cites] Leuk Lymphoma. 2002 Aug;43(8):1691-3 [12400615.001]
  • [Cites] J Comput Assist Tomogr. 1985 Jan-Feb;9(1):115-20 [2981908.001]
  • [Cites] Head Neck. 1993 Jan-Feb;15(1):62-6 [8416860.001]
  • [Cites] Surg Neurol. 1998 Nov;50(5):475-9 [9842876.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Feb;124(2):217-21 [11226960.001]
  • (PMID = 15981110.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Borka K: [Claudin expression in different pancreatic cancers and its significance in differential diagnostics]. Magy Onkol; 2009 Sep;53(3):273-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Changes in their expression pattern have been demonstrated in a number of tumors.
  • The aim of our studies was to compare the different CLDN expression patterns in normal pancreas cells, pancreatic endocrine tumors, adenocarcinomas, mucinous cystic tumors and acinar cell carcinomas.
  • ) In addition to the well-known CLDN-1 and -4 expression CLDN-2, -3 and -7 proteins were demonstrated in ductal cells, while CLDN-3 and -7 proteins showed expression in acinar cells.
  • 2.) CLDN-3 and -7 proteins showed high expression in endocrine tumors, CLDN-1, -2, and -4 proteins in exocrine tumors.
  • This is the first description of CLDN protein expression in endocrine tumors.
  • 3.) The level of CLDN-1, -4 and -7 protein expression in borderline cystic tumors is in between that of benign and malignant tumors.
  • This supports the sequential development theory regarding mucinous cystic tumors.
  • 4.) This is a first review on childhood acinar cell carcinoma causing Cushing syndrome.
  • The adenocarcinomas and cystic mucinous tumors of exocrine origin denoted CLDN-1, -2, -4 and -7 positivity, whereas acinar cell carcinomas expressed only CLDN-1 and -2.
  • Considering the CLDN expression observed in normal pancreas cells, it can be established that CLDN-1, -2 and -4 proteins are definitely markers of ductal differentiation, CLDN-1 protein of acinar and CLDN-3 of endocrine differentiation. 2).
  • The increased CLDN-4 expression in adenocarcinomas and mucinous cystic tumors, as well as the high CLDN-3 expression in endocrine tumors may open up new prospects in the targeted therapy of these tumors. 3).
  • The claudin expression pattern of pancreas tumors may be employed in the differential diagnosis of these tumors and may be of help in deciding dignity.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Claudins / metabolism. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / metabolism. Claudin-1. Claudin-3. Claudin-4. Cystadenocarcinoma, Mucinous / diagnosis. Cystadenocarcinoma, Mucinous / metabolism. Diagnosis, Differential. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Luminescence. Membrane Proteins / metabolism. Microscopy, Electron. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19793693.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN1 protein, human; 0 / CLDN2 protein, human; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / CLDN7 protein, human; 0 / Claudin-1; 0 / Claudin-3; 0 / Claudin-4; 0 / Claudins; 0 / Membrane Proteins
  •  go-up   go-down


52. Canzonieri V: [EUS-FNA cytology of pancreatic exocrine tumors. Comparison of experiences with pathological diagnosis]. Minerva Med; 2007 Aug;98(4):367-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [EUS-FNA cytology of pancreatic exocrine tumors. Comparison of experiences with pathological diagnosis].
  • EUS-FNA provides a safe and accurate mean to diagnose pancreatic tumors in early and advanced stages.
  • A personal observation of a case of acinic cell carcinoma is briefly presented, with extensive cytological iconography of routinely stained smears, integrated with cytochemical/immunocytochemical analysis for diagnostic purposes.
  • [MeSH-minor] Carcinoma / pathology. Carcinoma / ultrasonography. Humans. Neoplasm Staging / methods. Pancreatic Pseudocyst / pathology. Pancreatic Pseudocyst / ultrasonography. Ultrasonography, Interventional / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17921952.001).
  • [ISSN] 0026-4806
  • [Journal-full-title] Minerva medica
  • [ISO-abbreviation] Minerva Med.
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 13
  •  go-up   go-down


53. Guo J, Kleeff J, Zhao Y, Li J, Giese T, Esposito I, Büchler MW, Korc M, Friess H: Yes-associated protein (YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma. Int J Mol Med; 2006 May;17(5):761-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yes-associated protein (YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma.
  • Pancreatic ductal adenocarcinoma (PDAC) is characterized by multiple alterations in the TGF-beta signaling pathway.
  • YAP65 mRNA expression levels in human pancreatic tissue samples and cell lines were analyzed by Northern blotting and quantitative RT-PCR.
  • In the normal pancreas, YAP65 was absent in acinar cells, large ducts and islet cells, but exhibited moderate to strong immunoreactivity in centroacinar cells and ductules.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Adenocarcinoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology. Phosphoproteins / genetics. Smad7 Protein / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blotting, Northern. Blotting, Western. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Immunohistochemistry. Male. Middle Aged. Mutation. RNA, Messenger / genetics. RNA, Messenger / metabolism. Smad4 Protein / genetics. Transforming Growth Factor beta / pharmacology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596258.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-75059
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Phosphoproteins; 0 / RNA, Messenger; 0 / SMAD4 protein, human; 0 / SMAD7 protein, human; 0 / Smad4 Protein; 0 / Smad7 Protein; 0 / Transforming Growth Factor beta; 0 / YAP1 (Yes-associated) protein, human
  •  go-up   go-down


54. Chiosea SI, Peel R, Barnes EL, Seethala RR: Salivary type tumors seen in consultation. Virchows Arch; 2009 Apr;454(4):457-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary type tumors seen in consultation.
  • Seven hundred sixty consultation requests were prospectively indexed over 12 months, and 205 cases of salivary type tumors were identified.
  • Final diagnosis was offered by submitting pathologist in 77 of 205 cases (37.5%).
  • The definitive diagnosis was provided to contributors in 188 of 205 cases (91.7%); diagnostic limitations and potential adequacy issues were addressed in 17 remaining cases.
  • The three most common diagnostic problems were acinic cell carcinoma, epithelial myoepithelial carcinoma, and adenoid cystic carcinoma.
  • [MeSH-major] Referral and Consultation / standards. Referral and Consultation / statistics & numerical data. Salivary Gland Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Virchows Arch. 2011 Jul;459(1):117-8 [21638010.001]
  • [Cites] Arch Pathol Lab Med. 1995 Jun;119(6):514-7 [7605166.001]
  • [Cites] Head Neck. 2002 Jul;24(7):684-93 [12112543.001]
  • [Cites] J Am Board Fam Pract. 1994 Sep-Oct;7(5):371-4 [7810353.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):874-80 [15958851.001]
  • [Cites] Head Neck Pathol. 2007 Dec;1(2):123-31 [20614263.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):796-803 [9024718.001]
  • [Cites] Obstet Gynecol. 1998 May;91(5 Pt 1):730-4 [9572220.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2005 Apr;13(2):81-4 [15761280.001]
  • [Cites] Am J Surg Pathol. 2007 Nov;31(11):1683-94 [18059225.001]
  • [Cites] Am J Clin Pathol. 1989 Mar;91(3):348-54 [2923097.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Sep;127(9):1075-9 [11556855.001]
  • [Cites] Am J Surg Pathol. 1989 Oct;13(10):879-99 [2675654.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1994 Jan;77(1):19-26 [8108090.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):207-19 [10421256.001]
  • [Cites] Ann Pathol. 2007 Oct;27(5):345-51 [18185469.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2426-35 [10590387.001]
  • [Cites] Mod Pathol. 1998 Nov;11(11):1033-8 [9831198.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):743-5 [8068052.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):851-7 [8669533.001]
  • [Cites] J Urol. 2005 Oct;174(4 Pt 1):1390-4; discussion 1394; author reply 1394 [16145444.001]
  • [Cites] Eur J Surg Oncol. 2001 Sep;27(6):589-94 [11520094.001]
  • [Cites] Arch Pathol Lab Med. 2009 Jun;133(6):950-9 [19492889.001]
  • [Cites] Am J Surg Pathol. 2007 Jan;31(1):44-57 [17197918.001]
  • (PMID = 19271235.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


55. Distler M, Rückert F, Dittert DD, Stroszczynski C, Dobrowolski F, Kersting S, Grützmann R: Curative resection of a primarily unresectable acinar cell carcinoma of the pancreas after chemotherapy. World J Surg Oncol; 2009;7:22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curative resection of a primarily unresectable acinar cell carcinoma of the pancreas after chemotherapy.
  • BACKGROUND: Acinar cell carcinoma (ACC) represents only 1-2% of pancreatic cancers and is a very rare malignancy.
  • At the time of diagnosis only 50% of the tumors appear to be resectable.
  • MRI-imaging showed a tumor within the head of the pancreas concomitant with Serum-Lipase and CA19-9.
  • Endosonographic fine needle biopsy confirmed an acinar cell carcinoma.
  • Laparotomy presented an locally advanced tumor with venous infiltration that was consequently deemed unresectable.
  • Twelve months later, the patient was in stable condition, and CT-scanning showed an obvious reduction in the size of the tumor.
  • Histopathological examination gave evidence of a diffuse necrotic ACC-tumor, all resection margins were found to be negative.
  • Eighteen months later, the patient showed no signs of recurrent disease.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Acinar Cell / drug therapy. Carcinoma, Acinar Cell / surgery. Fluorouracil / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):222-5 [10982618.001]
  • [Cites] J Gastrointest Surg. 2008 Jun;12(6):1061-7 [17957440.001]
  • [Cites] Adv Anat Pathol. 2001 May;8(3):144-59 [11345238.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] Pathol Res Pract. 2002;198(12):777-83 [12608654.001]
  • [Cites] Pancreas. 2003 Jul;27(1):e18-22 [12826914.001]
  • [Cites] Int J Gastrointest Cancer. 2003;34(2-3):67-72 [15361637.001]
  • [Cites] Br Med J. 1970 Jun 20;2(5711):708-9 [5429656.001]
  • [Cites] Cancer. 1974 Apr;33(4):1002-9 [4819206.001]
  • [Cites] J Clin Pathol. 1977 Feb;30(2):103-12 [845259.001]
  • [Cites] Radiology. 1979 Feb;130(2):345-6 [760147.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Gastroenterol Jpn. 1992 Dec;27(6):785-91 [1281798.001]
  • [Cites] Dig Surg. 1999;16(1):76-9 [9949272.001]
  • [Cites] AJR Am J Roentgenol. 2005 Feb;184(2):511-9 [15671372.001]
  • [Cites] Pancreas. 2007 Jul;35(1):42-6 [17575544.001]
  • [Cites] JOP. 2007;8(6):783-9 [17993731.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):938-44 [10987254.001]
  • (PMID = 19239719.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2657786
  •  go-up   go-down


56. Tanahashi C, Yabuki S, Akamine N, Yatabe Y, Ichihara S: Pure acinic cell carcinoma of the breast in an 80-year-old Japanese woman. Pathol Int; 2007 Jan;57(1):43-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure acinic cell carcinoma of the breast in an 80-year-old Japanese woman.
  • Acinic cell carcinoma of the breast is an uncommon neoplasm.
  • Since the first case of this rare variant of breast carcinoma was reported in 1996, only 10 cases have been reported in the English-language literature.
  • Reported herein is the first case of primary acinic cell carcinoma of the breast in a Japanese woman.
  • To the naked eye, the tumor appeared well circumscribed and the cut surface was grayish-pink and hemorrhaging.
  • Microscopically, the tumor was predominantly made up of a monotonous proliferation of cells with a finely granular cytoplasm, resembling acinic cells of the parotid gland.
  • In spite of extensive sampling, no common histological patterns of breast carcinoma such as in situ and invasive ductal carcinoma were recognized in the present case, indicating that the present case was pure acinic cell carcinoma.
  • In addition, the immunohistochemical profile of this tumor was identical to that of the acinic cell carcinoma of the salivary gland: estrogen receptor, progesterone receptor, HER2 and cytokeratin (CK)20 were negative and amylase and CK7 were positive.
  • The patient has been well for 22 months since the wide local excision of the tumor and no signs of salivary neoplasm are evident to date.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / pathology


57. Jamieson L, Taylor SM, Smith A, Bullock MJ, Davis M: Metastatic acinic cell carcinoma of the parotid gland with ectopic ACTH syndrome. Otolaryngol Head Neck Surg; 2007 Jan;136(1):149-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic acinic cell carcinoma of the parotid gland with ectopic ACTH syndrome.
  • [MeSH-major] ACTH Syndrome, Ectopic / complications. Carcinoma, Acinar Cell / complications. Carcinoma, Acinar Cell / secondary. Parotid Neoplasms / complications. Parotid Neoplasms / pathology

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17210357.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Suzzi MV, Alessi A, Bertarelli C, Cancellieri A, Procaccio L, Dall'olio D, Laudadio P: Prognostic relevance of cell proliferation in major salivary gland carcinomas. Acta Otorhinolaryngol Ital; 2005 Jun;25(3):161-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic relevance of cell proliferation in major salivary gland carcinomas.
  • Several proliferation markers, such as DNA ploidy, Ki67, MiB1 and proliferating cell nuclear antigen have been shown to correlate with clinical course and prognosis in several epithelial tumours and lymphomas.
  • In the present study, the prognostic relevance of these markers was evaluated in major salivary gland carcinomas.
  • A sample of 36 cases out of 85 patients submitted to surgery for major salivary gland carcinomas at our institution between 1987 and 1997 were studied.
  • The sample comprised 8 adenoid-cystic carcinomas, 6 ductal carcinomas, 11 mucoepidermoid carcinomas and 11 acinic cell carcinomas.
  • Instead, the proliferative tumour cell fraction, evaluated by MiB1, was statistically correlated with prognosis.
  • Of particular interest were MiB1 values in acinic cell carcinomas for which grading is challenging and lacks consensus.
  • In our group of acinic cell carcinomas, survival correlated with values of MiB1 > or < 15 with p = 0.009 in Log rank test.
  • Indeed, "growth fraction" in acinic cell carcinomas may stratify different classes of risk.
  • [MeSH-major] Carcinoma / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Cell Proliferation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Ploidies. Prognosis

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1040-4 [15252310.001]
  • [Cites] J Clin Pathol. 1998 Oct;51(10):716-24 [10023332.001]
  • [Cites] J Histochem Cytochem. 1983 Nov;31(11):1333-5 [6619538.001]
  • [Cites] Cancer. 1984 Oct 15;54(8):1620-4 [6089994.001]
  • [Cites] Cytometry. 1989 May;10(3):229-41 [2653738.001]
  • [Cites] J Laryngol Otol. 1990 May;104(5):410-6 [2370468.001]
  • [Cites] J Laryngol Otol. 2001 Aug;115(8):639-44 [11535145.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1990 Nov;99(11):929-33 [2241022.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):379-85 [1617588.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1503-12 [7688652.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Jul;120(7):727-33 [8018325.001]
  • [Cites] Hum Pathol. 1994 Sep;25(9):929-35 [8088769.001]
  • [Cites] J Pathol. 1994 May;173(1):13-21 [7931834.001]
  • [Cites] Otolaryngol Head Neck Surg. 1994 Oct;111(4):460-6 [7936679.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994 Sep;30B(5):329-34 [7703802.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):223-30 [8625227.001]
  • [Cites] Hum Pathol. 1996 Jun;27(6):561-6 [8666365.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):958-67 [8780532.001]
  • [Cites] Head Neck. 1997 Mar;19(2):126-33 [9059870.001]
  • [Cites] Laryngoscope. 1997 Apr;107(4):531-6 [9111386.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1997;254(4):180-5 [9151016.001]
  • [Cites] J Pathol. 1997 Mar;181(3):323-9 [9155720.001]
  • [Cites] Hum Pathol. 1997 May;28(5):595-600 [9158708.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1319-29 [15319236.001]
  • (PMID = 16450771.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  • [Other-IDs] NLM/ PMC2639871
  •  go-up   go-down


59. Mai KT, Kohler DM, Belanger EC, Robertson SJ, Wang D: Sporadic clear cell renal cell carcinoma with diffuse cytokeratin 7 immunoreactivity. Pathology; 2008 Aug;40(5):481-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic clear cell renal cell carcinoma with diffuse cytokeratin 7 immunoreactivity.
  • AIMS: Clear cell renal cell carcinoma (CRCC) with diffuse immunoreactivity for CK7 is described.
  • Areas of regenerative epithelial cell nests (REC) were also examined.
  • Architecturally, CK7 positive CRCC consisted of cysts and solid cell nests with tubulo-acinar formations or papillary formations.
  • The ten patients with 21 CK7 positive CRCC developed no metastatic disease over a follow up time that ranged from 1 to 10 years (mean of 3 years).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Renal Cell / metabolism. Keratin-7 / biosynthesis. Kidney Neoplasms / metabolism

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604734.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-7; EC 3.4.24.11 / Neprilysin; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


60. Yamashita R, Matsuzaki M, Matsui T, Yamaguchi R, Yuen K, Niwakawa M, Tobisu K: [Clinical characteristics of prostatic adenocarcinoma with ductal features]. Nihon Hinyokika Gakkai Zasshi; 2008 Mar;99(3):525-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics of prostatic adenocarcinoma with ductal features].
  • PURPOSE: To determine the incidence and prognosis of prostatic ductal adenocarcinoma.
  • We differentiated prostatic cases of ductal adenocarcinoma that were larger than 5 mm in diameter from cases of acinar adenocarcinomas.
  • RESULTS: We found eight cases (12%) of prostatic ductal adenocarcinoma among the 64 cases treated with radical prostatectomies.
  • Seven of the cases (11%) were mixed-type ductal adenocarcinomas, which contained acinar and ductal components.
  • In addition, one case was identified as pure ductal adenocarcinoma.
  • During the follow-up period, four of the eight cases of ductal adenocarcinoma (50%) and twelve of the 56 cases of acinar adenocarcinoma (21%) showed postoperative PSA failure.
  • CONCLUSIONS: We identified eight cases of ducal adenocarcinoma (12% of the examined cases), which suggests this disease is not as rare as previously reported.
  • Compared to the cases of acinar adenocarcinoma, the cases of ductal adenocarcinoma were at a more advanced pathological stage and resulted in a higher rate of postoperative PSA failure.
  • Therefore, we believe that patients that show even a limited degree of ductal adenocarcinoma should receive aggressive therapy.
  • [MeSH-major] Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / therapy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / therapy. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Neoplasms, Multiple Primary. Prognosis. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404881.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


61. Kayed H, Bekasi S, Keleg S, Michalski CW, Giese T, Friess H, Kleeff J: BGLAP is expressed in pancreatic cancer cells and increases their growth and invasion. Mol Cancer; 2007;6:83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we analyzed the expression and role of BGLAP in the normal human pancreas, chronic pancreatitis (CP), and pancreatic ductal adenocarcinoma (PDAC) using quantitative RT-PCR, immunohistochemistry, immunocytochemistry and enzyme immunoassays, as well as cell proliferation and invasion assays.
  • BGLAP was faintly present in the cytoplasm of normal acinar cells but was strongly expressed in the cytoplasm and nuclei of tubular complexes and PanIN lesions of CP and PDAC tissues.
  • Furthermore, BGLAP expression was found in the cancer cells in PDAC tissues as well as in 4 cultured pancreatic cancer cell lines.
  • TNFalpha reduced BGLAP mRNA and protein expression levels in pancreatic cancer cell lines.
  • In addition, BGLAP silencing led to reduction of both cell growth and invasion in those cells.
  • CONCLUSION: BGLAP is expressed in pancreatic cancer cells, where it potentially increases pancreatic cancer cell growth and invasion through autocrine and/or paracrine mechanisms.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Pancreatic Ductal / genetics. Cell Proliferation. Gene Expression Regulation, Neoplastic / physiology. Osteocalcin / genetics. Pancreatic Neoplasms / genetics

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):742-50 [17943729.001]
  • [Cites] Ann Surg. 2007 Nov;246(5):786-93 [17968170.001]
  • [Cites] Lab Invest. 2003 Jun;83(6):853-9 [12808120.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Int J Cancer. 2004 Jul 10;110(5):668-76 [15146555.001]
  • [Cites] Curr Gastroenterol Rep. 2004 Apr;6(2):111-8 [15191688.001]
  • [Cites] Pancreas. 2004 Jul;29(1):45-52 [15211111.001]
  • [Cites] Proc Natl Acad Sci U S A. 1976 May;73(5):1447-51 [1064018.001]
  • [Cites] J Biol Chem. 1980 Jul 25;255(14):6579-83 [6967067.001]
  • [Cites] Am J Surg. 1982 Aug;144(2):243-9 [7102934.001]
  • [Cites] Dtsch Med Wochenschr. 1985 Sep 20;110(38):1442-6 [3875469.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Sep;82(18):6109-13 [3875856.001]
  • [Cites] Haemostasis. 1986;16(3-4):258-72 [3530901.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jun;86(12):4455-9 [2786632.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6665-9 [1353882.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2704-7 [8389240.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1846-56 [8253361.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Dec 30;205(3):1815-21 [7529022.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):824-31 [7547227.001]
  • [Cites] Nature. 1996 Aug 1;382(6590):448-52 [8684484.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4614-9 [8840973.001]
  • [Cites] Mol Endocrinol. 1996 Nov;10(11):1444-56 [8923469.001]
  • [Cites] Eur J Haematol. 1997 Feb;58(2):104-8 [9111591.001]
  • [Cites] Cell. 1997 May 30;89(5):747-54 [9182762.001]
  • [Cites] Cell. 1997 May 30;89(5):755-64 [9182763.001]
  • [Cites] Int J Pancreatol. 1997 Apr;21(2):119-26 [9209953.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1677-83 [9563482.001]
  • [Cites] Bone. 1998 Sep;23(3):187-96 [9737340.001]
  • [Cites] Cancer Gene Ther. 1998 Sep-Oct;5(5):274-80 [9824046.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4554-9 [9845520.001]
  • [Cites] Gastroenterology. 1999 May;116(5):1202-16 [10220513.001]
  • [Cites] Prostate. 1999 Jun 1;39(4):246-61 [10344214.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):224-34 [16041213.001]
  • [Cites] Cancer Biol Ther. 2005 Jul;4(7):740-6 [15970685.001]
  • [Cites] Pol Merkur Lekarski. 2005 Jul;19(109):94-7 [16194038.001]
  • [Cites] Int J Biol Markers. 2005 Jul-Sep;20(3):146-55 [16240842.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Mar;7(5):346-53 [17562244.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):21-32 [17290391.001]
  • [Cites] Cancer Treat Rev. 2006;32 Suppl 1:15-9 [16680833.001]
  • [Cites] Br J Cancer. 2007 Oct 22;97(8):1106-15 [17876328.001]
  • [Cites] Mol Cell Biol. 2001 Apr;21(8):2891-905 [11283267.001]
  • (PMID = 18163903.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 104982-03-8 / Osteocalcin; 119978-18-6 / matrigel; 9007-34-5 / Collagen
  • [Other-IDs] NLM/ PMC2245975
  •  go-up   go-down


62. Gong Y, Caraway N, Stewart J, Staerkel G: Metastatic ductal adenocarcinoma of the prostate: cytologic features and clinical findings. Am J Clin Pathol; 2006 Aug;126(2):302-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic ductal adenocarcinoma of the prostate: cytologic features and clinical findings.
  • We retrospectively reviewed the cytologic features of metastatic prostatic ductal carcinoma (PDC) in 23 cases, clinical manifestations, and clinical outcomes.
  • Cytologic smears typically showed tumor cells with abundant cytoplasm and oval nuclei arranged in papillary groups or flat and folded sheets, some of which showed peripheral nuclear palisading.
  • However, these features could be focal, subtle, and even indistinguishable from those of acinar carcinoma, particularly when the ductal component was predominantly of a cribriform and solid pattern or coexisted with acinar carcinoma.
  • Immunostaining for prostate-specific antigen and prostatic acid phosphatase proved helpful in determining a definitive diagnosis.
  • Tumor growth pattern did not correlate with prognosis, but visceral metastasis conveyed a poor prognosis.
  • The correlation with clinical and radiologic findings, a high index of suspicion, and the use of immunoperoxidase studies are important in making an accurate diagnosis.
  • [MeSH-major] Carcinoma, Ductal / secondary. Prostatic Neoplasms / pathology
  • [MeSH-minor] Acid Phosphatase. Aged. Biomarkers, Tumor / analysis. Biopsy, Needle. Humans. Immunoenzyme Techniques. Male. Middle Aged. Prognosis. Prostate-Specific Antigen / analysis. Protein Tyrosine Phosphatases / analysis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16891207.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


63. Rajpal S, Warren RS, Alexander M, Yeh BM, Grenert JP, Hintzen S, Ljung BM, Bergsland EK: Pancreatoblastoma in an adult: case report and review of the literature. J Gastrointest Surg; 2006 Jun;10(6):829-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An initial fine needle aspiration of the pancreatic mass was nondiagnostic, and a subsequent fine needle aspiration of a liver mass was read as metastatic acinar cell carcinoma.
  • The patient underwent a palliative resection for tumor-associated pain and gastrointestinal hemorrhage that revealed a large pancreatic tumor invading through the full thickness of the colon at the splenic flexure and adherent to the posterior gastric wall.
  • The pathology from the distal pancreatectomy, splenectomy, partial gastrectomy, partial colectomy, and cholecystectomy unexpectedly supported a diagnosis of pancreatoblastoma with evidence for squamoid corpuscles as well as areas of acinar formation.
  • Despite multiple chemotherapy regimens, the patient's disease continued to progress in the liver and the lungs.
  • During the course of his therapy, the patient's serum alpha-fetoprotein levels and serum lipase levels rose concurrently, suggesting tumor-associated production of both of these factors.
  • Seventeen months after the diagnosis of metastatic pancreatoblastoma, the patient died from his disease.
  • Our case illustrates the fact that pancreatoblastomas are extremely difficult to diagnosis preoperatively.
  • [MeSH-minor] Abdominal Pain / etiology. Biopsy, Fine-Needle. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / secondary. Disease Progression. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Male. Middle Aged. Nausea / etiology. Neoplasm Invasiveness. Satiety Response. Splenic Vein / diagnostic imaging. Splenic Vein / pathology. Stomach / pathology. Tomography, X-Ray Computed. Vomiting / etiology

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1995 Jun;119(6):547-51 [7605173.001]
  • [Cites] Am J Gastroenterol. 1996 Sep;91(9):1841-4 [8792711.001]
  • [Cites] Hum Pathol. 1992 Jul;23(7):828-30 [1377164.001]
  • [Cites] Am J Pathol. 1993 Sep;143(3):685-98 [8362971.001]
  • [Cites] Gastroenterol Clin Biol. 1997;21(11):880-3 [9587540.001]
  • [Cites] J Pediatr Surg. 2002 Jun;37(6):887-92 [12037756.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] Med Pediatr Oncol. 2001 Jul;37(1):47-52 [11466723.001]
  • [Cites] Pancreatology. 2004;4(5):441-51; discussion 452-3 [15256806.001]
  • [Cites] Radiol Med. 2002 Jan-Feb;103(1-2):119-22 [11859308.001]
  • [Cites] Arch Pathol Lab Med. 2003 Nov;127(11):1501-5 [14567752.001]
  • [Cites] Virchows Arch. 1994;424(5):485-90 [8032529.001]
  • [Cites] Arch Pathol Lab Med. 1986 Jul;110(7):650-2 [3013120.001]
  • [Cites] Chirurg. 2001 Jul;72(7):806-11 [11490758.001]
  • [Cites] Radiology. 2000 Feb;214(2):476-82 [10671596.001]
  • [Cites] Adv Anat Pathol. 2001 May;8(3):144-59 [11345238.001]
  • [Cites] J Gastroenterol. 1998 Oct;33(5):761-5 [9773947.001]
  • [Cites] World J Surg. 1998 Aug;22(8):879-82 [9673563.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1371-89 [7503360.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1619-27 [11696422.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1340-2 [11677959.001]
  • (PMID = 16769539.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


64. Flury SC, Galgano MT, Mills SE, Smolkin ME, Theodorescu D: Atypical small acinar proliferation: biopsy artefact or distinct pathological entity? BJU Int; 2007 Apr;99(4):780-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical small acinar proliferation: biopsy artefact or distinct pathological entity?
  • OBJECTIVE: To determine if atypical small acinar proliferation (ASAP) represents minimally sampled prostate cancer not fully evaluated on a biopsy or a distinct pathological entity, by examining prostates removed at radical cystectomy, as a finding of ASAP of the prostate on needle-core biopsy is closely associated with the detection of cancer on subsequent biopsy.
  • The presence of high-grade prostatic intraepithelial neoplasia (HGPIN), ASAP, and adenocarcinoma was recorded.
  • RESULTS: In all, 24 of 65 specimens (37%) had adenocarcinoma.
  • The remaining eight foci all lacked CK903 stain, indicating disruption of the basal cell layer.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Acinar Cell / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Cell Proliferation. Cystectomy / methods. Humans. Immunohistochemistry. Male. Middle Aged. Predictive Value of Tests. Prostate / pathology. Prostatectomy / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378841.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Tonini G, Rosini R, Teppa A, Aulenti V, Kalantary F, Tosana M, Bianchi D, Zorzi F: [Adenoid cystic/basal cell carcinoma of the prostate:case report]. Urologia; 2008 Oct-Dec;75(4):245-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic/basal cell carcinoma of the prostate:case report].
  • Although most prostate carcinomas belong to the conventional acinar type, unusual variants have been reported.
  • The adenoid cystic/basal cell carcinoma of the prostate is a rare tumor with distinctive histopathologic features.
  • There are quite few publications in the literature concerning the diagnosis, treatment, and prognosis of this neoplasm.
  • METHODS. A 71-year-old man had an increased PSA value (5.11 ng/dL); the prostatic biopsy examination was positive for adenoid cystic/basal cell carcinoma.
  • The histology examination showed an acinar conventional carcinoma and adenoid cystic/basal cell carcinoma.
  • CONCLUSIONS. Various histologic and immunohistochemical features are helpful in recognizing the adenoid cystic/basal cell carcinoma of the prostate.
  • Clinically, the only difference from a conventional adenocarcinoma is that the PSA value is usually normal or only slightly increased.
  • This tumor has a biological potential that can result in metastases in some cases; the current treatment consists primarily in the surgical resection.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086341.001).
  • [ISSN] 0391-5603
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Inamura K, Togashi Y, Nomura K, Ninomiya H, Hiramatsu M, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y: let-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a non-invasive carcinoma, and is not correlated with prognosis. Lung Cancer; 2007 Dec;58(3):392-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] let-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a non-invasive carcinoma, and is not correlated with prognosis.
  • In this study, we examined 15 early bronchioloalveolar carcinomas (BACs), usually considered as adenocarcinomas in situ, as well as 26 well-differentiated and 25 less-differentiated invasive adenocarcinomas, to assess the association between tumor progression and let-7 expression levels.
  • Additionally, we investigated 47 invasive lung adenocarcinomas for EGFR and KRAS mutations and correlations with let-7 levels.
  • Relative to the corresponding normal lung tissue, reduced let-7 expression was observed in 13 of 15 BACs (87%) and totally in 52 of the 66 adenocarcinomas (79%), suggesting a link with early occurrence in carcinogenesis.
  • On classification of adenocarcinomas into two groups according to let-7 expression, no prognostic or genetic differences were observed.
  • Interestingly, some differences between histological subtypes were observed, such as lower let-7 expression levels in acinar adenocarcinomas and mucinous BACs.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Gene Expression Regulation, Neoplastic / genetics. MicroRNAs / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lung Cancer. 2008 May;60(2):307 [18395292.001]
  • (PMID = 17728006.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / mirnlet7 microRNA, human
  •  go-up   go-down


67. Dickinson SI: Premalignant and malignant prostate lesions: pathologic review. Cancer Control; 2010 Oct;17(4):214-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Premalignant and malignant prostate lesions: pathologic review.
  • BACKGROUND: High-grade prostatic intraepithelial neoplasia (HGPIN) is currently the only recognized premalignant lesion of prostatic carcinoma.
  • METHODS: This review article discusses HGPIN, its link to prostatic adenocarcinoma, and the significance of its presence on needle biopsy.
  • The criteria and clinical impact of the diagnosis of atypical small acinar proliferation on needle biopsy are reviewed.
  • Histologic variants of prostatic adenocarcinoma with distinct cell types are also described.
  • RESULTS: HGPIN is the only known pathologic factor currently available to distinguish which patients may be at risk for detecting carcinoma on repeat biopsy.
  • Histologic variants are recognized due to the inference of a particular Gleason grade pattern associated with the cell type, hence affecting prognosis.
  • CONCLUSIONS: HGPIN has a strong association with acinar-type prostatic adenocarcinoma.
  • HGPIN and acinar-type prostatic adenocarcinoma both show similar molecular alterations, providing further evidence of their association.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Carcinoma, Acinar Cell / pathology. Humans. Male. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20861809.001).
  • [ISSN] 1526-2359
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


68. Flores LG, Bertolini S, Yeh HH, Young D, Mukhopadhyay U, Pal A, Ying Y, Volgin A, Shavrin A, Soghomonyan S, Tong W, Bornmann W, Alauddin MM, Logsdon C, Gelovani JG: Detection of pancreatic carcinomas by imaging lactose-binding protein expression in peritumoral pancreas using [18F]fluoroethyl-deoxylactose PET/CT. PLoS One; 2009 Nov 24;4(11):e7977
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of pancreatic carcinomas by imaging lactose-binding protein expression in peritumoral pancreas using [18F]fluoroethyl-deoxylactose PET/CT.
  • BACKGROUND: Early diagnosis of pancreatic carcinoma with highly sensitive diagnostic imaging methods could save lives of many thousands of patients, because early detection increases resectability and survival rates.
  • Current non-invasive diagnostic imaging techniques have inadequate resolution and sensitivity for detection of small size ( approximately 2-3 mm) early pancreatic carcinoma lesions.
  • Therefore, we have assessed the efficacy of positron emission tomography and computer tomography (PET/CT) imaging with beta-O-D-galactopyranosyl-(1,4')-2'-deoxy-2'-[(18)F]fluoroethyl-D-glucopyranose ([(18)F]FEDL) for detection of less than 3 mm orthotopic xenografts of L3.6pl pancreatic carcinomas in mice.
  • [(18)F]FEDL is a novel radioligand of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein (HIP/PAP), which is overexpressed in peritumoral pancreatic acinar cells.
  • The in situ analysis demonstrated that at least a 2-4 fold apparent lesion size amplification was achieved for submillimeter tumors and to nearly half a murine pancreas for tumors larger than 3 mm.
  • CONCLUSION/SIGNIFICANCE: We have demonstrated the feasibility of detection of early pancreatic tumors by non-invasive imaging with [(18)F]FEDL PET/CT of tumor biomarker HIP/PAP over-expressed in peritumoral pancreatic tissue.
  • Non-invasive non-invasive detection of early pancreatic carcinomas with [(18)F]FEDL PET/CT imaging should aid the guidance of biopsies and additional imaging procedures, facilitate the resectability and improve the overall prognosis.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Lactose .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2003 May;124(5):1292-9 [12730869.001]
  • [Cites] Pancreatology. 2001;1(1):43-7 [12120267.001]
  • [Cites] FASEB J. 2003 Aug;17(11):1441-50 [12890698.001]
  • [Cites] FEBS Lett. 1994 Jan 3;337(1):114-8 [8276102.001]
  • [Cites] J Cereb Blood Flow Metab. 1996 Sep;16(5):834-40 [8784228.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Ann Intern Med. 1999 Aug 17;131(4):247-55 [10454945.001]
  • [Cites] Curr Opin Struct Biol. 1999 Oct;9(5):585-90 [10508765.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):779-87 [15791284.001]
  • [Cites] Biochim Biophys Acta. 2005 May 25;1723(1-3):8-18 [15715980.001]
  • [Cites] World J Gastroenterol. 2005 Sep 7;11(33):5199-202 [16127752.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1361-9 [16211233.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10613-22 [16288055.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):252-8 [16344318.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2066-9 [16609017.001]
  • [Cites] Semin Nucl Med. 2006 Jul;36(3):248-56 [16762614.001]
  • [Cites] Hum Pathol. 2006 Aug;37(8):1066-75 [16867870.001]
  • [Cites] Cancer Biol Ther. 2007 Jun;6(6):948-56 [17611392.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 May;35(5):990-8 [18057932.001]
  • [Cites] Pancreatology. 2008;8(2):110-25 [18382097.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4819-26 [18559529.001]
  • [Cites] Pancreas. 2009 Jul;38(5):527-33 [19342980.001]
  • [Cites] Mol Imaging Biol. 2011 Jun;13(3):536-46 [20593279.001]
  • [Cites] Am J Pathol. 1999 Nov;155(5):1525-33 [10550309.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):409-16 [10667595.001]
  • [Cites] Neoplasia. 1999 Apr;1(1):50-62 [10935470.001]
  • [Cites] J Surg Oncol. 2000 Aug;74(4):243-8 [10962454.001]
  • [Cites] Gastroenterology. 2000 Dec;119(6):1447-53 [11113065.001]
  • [Cites] Dig Dis. 2001;19(1):76-84 [11385254.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2B):1471-4 [11396234.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1868-75 [11912167.001]
  • [Cites] Dig Dis Sci. 2003 Mar;48(3):459-64 [12757156.001]
  • (PMID = 19956730.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA126577; United States / NCI NIH HHS / CA / U24 CA126577-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Fluorine Radioisotopes; 0 / Lectins, C-Type; 0 / Ligands; 0 / O-galactopyranosyl-(1-4')-2'-deoxy-2'-fluoroethylglucopyranose; 0 / Radiopharmaceuticals; 0 / pancreatitis-associated protein; J2B2A4N98G / Lactose
  • [Other-IDs] NLM/ PMC2776527
  •  go-up   go-down


69. Kitoh H, Ryozawa S, Harada T, Kondoh S, Furuya T, Kawauchi S, Oga A, Okita K, Sasaki K: Comparative genomic hybridization analysis for pancreatic cancer specimens obtained by endoscopic ultrasonography-guided fine-needle aspiration. J Gastroenterol; 2005 May;40(5):511-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor cells were selected by microdissection.
  • RESULTS: In the 15 patients with tubular adenocarcinoma, the most common loci of gains (including amplification) were 5p, 8q, and 20q (60% of the patients); and 1q, 7p, and 12p (27%).
  • Both of the patients with acinar cell carcinoma showed gains of 2q and 5p, and losses of 1p, 9p, 9q, 11p, 11q, 14q, 17p, 17q, and 18q.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / ultrasonography. Biopsy, Fine-Needle / methods. Nucleic Acid Hybridization. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / ultrasonography

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942717.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


70. Li J, Yang SJ, Zhao XL, Zhang YQ, Li KN, Cui JH, Li J: [Significant increase of glucose transport activity in breast cancer]. Zhonghua Bing Li Xue Za Zhi; 2008 Feb;37(2):103-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the expression level and significance of glucose transporter 1 (Glut-1) in normal breast tissue, adenosis, adenoma and breast carcinoma.
  • METHODS: A total of 147 cases of female breast tissue samples, including 92 cases of invasive ductal carcinoma, 26 cases of breast fibroadenoma, 24 cases of breast adenosis and 5 cases of normal breast tissues, were collected for quantitative detection of the expression of Glut-1 protein by immunohistochemistry (EnVision method) and Western blot, and its mRNA by reverse transcriptase-polymerase chain reaction (RT-PCR).
  • RESULTS: In normal breast tissue and benign lesions of the breast, Glut-1 was undetectable or only weakly detectable in cytoplasm of ductal and acinar epithelia.
  • In contrast, the intensity of Glut-1 staining was significantly higher in invasive ductal carcinomas (P = 0.0002) with protein expression predominantly in cellular membrane and lesser in cytoplasm.
  • Western blot and RT-PCR analyses showed that the expression of Glut-1 protein and mRNA were significantly increased in invasive ductal carcinoma than fibroadenoma (P =0.001 for protein; P <0.05 for mRNA) and adenosis (P =0.001 for protein; P < 0.05 for mRNA).
  • CONCLUSIONS: Glucose transport activity, as indicated by Glut-1 protein and its mRNA expression, significantly increases in breast carcinoma than non-cancerous lesions.
  • The over-expression of Glut-1 in breast carcinoma is tightly coupled with tumor cell proliferation, invasion and metastasis, implying that Glut-1 may serve as a new marker in the early diagnosis and prognostication of breast malignancy as well as a new therapeutic target.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Gene Expression Regulation, Neoplastic. Glucose / physiology. Glucose Transporter Type 1 / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681321.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glucose Transport Proteins, Facilitative; 0 / Glucose Transporter Type 1; IY9XDZ35W2 / Glucose
  •  go-up   go-down


71. Ou SH, Ziogas A, Zell JA: Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung. J Thorac Oncol; 2010 Apr;5(4):420-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung.
  • BACKGROUND: The presence of signet-ring cell component has been described as a prominent feature of EML4-ALK positive non-small cell lung cancer.
  • We investigated the clinicopathologic features and survival outcome of primary signet-ring carcinoma (SRC) of the lung with comparison to adenocarcinoma of the lung.
  • METHODS: Retrospective population-based analysis of histologically diagnosed primary SRC of the lung in the California Cancer Registry between 1989 and 2006 with comparison with adenocarcinoma of the lung.
  • RESULTS: Two hundred sixty-two histologically diagnosed primary SRC of the lung were compared to 50,089 patients with lung adenocarcinoma.
  • Patients with primary SRC of the lung were significantly younger than patients with adenocarcinoma, with a significantly higher proportion of poorly differentiated tumor and stage IV disease.
  • There was no difference in the distribution of gender and ethnicity among patients with SRC when compared to patients with adenocarcinoma.
  • Subset analysis of patients with available smoking status revealed never smokers comprised a significantly higher proportion of patients with SRC (30.8%) when compared to patients with adenocarcinoma (11.0%; p = 0.0013).
  • Patients with SRC had decreased OS (versus adenocarcinoma; unadjusted hazard ratio = 1.507; 95% confidence interval: 1.326-1.714; p < 0.0001) and was an independent unfavorable prognostic factor by multivariate analysis (versus adenocarcinoma, hazard ratio 1.214, 95% confidence interval: 1.068-1.381; p = 0.0030).
  • CONCLUSIONS: Primary SRC of the lung is a rare subtype of adenocarcinoma, carries a worse prognosis when compared to adenocarcinoma and shares many of the recently identified clinicopathologic characteristics ascribed to EML4-ALK positive non-small cell lung cancer.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / epidemiology. Adenocarcinoma, Papillary / epidemiology. Carcinoma, Acinar Cell / epidemiology. Carcinoma, Signet Ring Cell / epidemiology. Lung Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20130484.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-35136; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / PC / N01-PC-54404
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EML4-ALK fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


72. Liu G, Zheng H, Zhang Z, Wu Z, Xiong H, Li J, Song L: Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy. BMC Cancer; 2010;10:495
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy.
  • The current study was to characterize the expression of SPHK1 in salivary gland carcinomas (SGC) and to investigate the association between SPHK1 expression and progression of SGC.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Phosphotransferases (Alcohol Group Acceptor) / metabolism. Salivary Gland Neoplasms / metabolism. Salivary Glands / metabolism
  • [MeSH-minor] Adenocarcinoma, Papillary / genetics. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Blotting, Western. Carcinoma, Acinar Cell / genetics. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cohort Studies. Disease Progression. Female. Gamma Rays. Humans. Immunoenzyme Techniques. Male. Middle Aged. Mucoepidermoid Tumor / genetics. Mucoepidermoid Tumor / metabolism. Mucoepidermoid Tumor / pathology. Palliative Care. Prognosis. RNA, Messenger / genetics. Radiotherapy, Adjuvant. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Res. 2003 May;47(5):401-7 [12676514.001]
  • [Cites] Histopathology. 2003 Apr;42(4):348-56 [12653946.001]
  • [Cites] J Atheroscler Thromb. 2003;10(3):125-31 [14564080.001]
  • [Cites] J Clin Pathol. 2003 Dec;56(12):914-8 [14645349.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):328-31 [14974865.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1040-4 [15252310.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(17):7359-69 [15314148.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] J Craniomaxillofac Surg. 1996 Jun;24(3):133-9 [8842902.001]
  • [Cites] Science. 1998 Mar 6;279(5356):1552-5 [9488656.001]
  • [Cites] Head Neck. 1999 Aug;21(5):414-9 [10402521.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3169-77 [15632208.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2526-33 [15900577.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Aug;64(8):695-705 [16106218.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1808-16 [15890687.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11667-75 [16357178.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 21;342(4):1284-90 [16516161.001]
  • [Cites] Leukemia. 2006 Jan;20(1):95-102 [16281067.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Aug;318(2):596-603 [16632640.001]
  • [Cites] Mol Cell Biol. 2006 Oct;26(19):7211-23 [16980623.001]
  • [Cites] Biochim Biophys Acta. 2006 Dec;1758(12):2016-26 [16996023.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2007 Jun;264(6):587-94 [17415578.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):729-34 [17350323.001]
  • [Cites] Anticancer Res. 2007 Sep-Oct;27(5B):3661-6 [17972532.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):54-8 [18091319.001]
  • [Cites] Leukemia. 2008 May;22(5):971-9 [18401414.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3319-26 [18519759.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1393-9 [19228740.001]
  • [Cites] J Cell Biol. 1999 Nov 1;147(3):545-58 [10545499.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):518-23 [10649241.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jun;124(6):836-9 [10835516.001]
  • [Cites] Curr Biol. 2000 Nov 30;10(23):1527-30 [11114522.001]
  • [Cites] Biochem J. 2000 Jul 15;349(Pt 2):385-402 [10880336.001]
  • [Cites] J Neurochem. 2001 Mar;76(5):1573-84 [11238741.001]
  • [Cites] Laryngorhinootologie. 2001 Sep;80(9):525-9 [11555785.001]
  • [Cites] Pathol Res Pract. 2001;197(9):621-6 [11569926.001]
  • [Cites] Biochim Biophys Acta. 2002 May 23;1582(1-3):72-80 [12069812.001]
  • [Cites] Transplant Proc. 2002 Aug;34(5):1784-5 [12176575.001]
  • [Cites] Exp Cell Res. 2002 Nov 15;281(1):115-27 [12441135.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 May;4(5):397-407 [12728273.001]
  • (PMID = 20846391.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.- / sphingosine kinase
  • [Other-IDs] NLM/ PMC2949806
  •  go-up   go-down


73. Piechocki MP, Dibbley SK, Lonardo F, Yoo GH: Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu. Int J Cancer; 2008 Apr 15;122(8):1722-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oral administration of gefitinib to female transgenic mice from 5 to 14 weeks of age reduced tumor multiplicity from 9.6 +/- 0.82 to 0.58 +/- 1.1 (83%).
  • We observed a decrease in the number and size of lobules and lobular nodules in treated mice with a reduction in the overall disease burden per gland.
  • The development of acinic cell carcinoma in the parotid glands of these animals was also reduced coincident with decreased stromal involvement during progression.
  • Gefitinib eliminated phosphorylation of HER2 and HER3 and signaling through MAPK and Akt in lobular hyperplasias and carcinomas.
  • These studies demonstrate the critical role of HER2 signal transduction in the onset and progression of HER2/neu-dependent breast cancer and suggest a role for specific inhibitors to prevent the outgrowth of early hyperplastic disease.
  • [MeSH-minor] Administration, Oral. Animals. Carcinoma, Acinar Cell / drug therapy. Carcinoma, Acinar Cell / prevention & control. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / prevention & control. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Mice. Mice, Inbred BALB C. Mice, Transgenic. Mitogen-Activated Protein Kinase Kinases / metabolism. Phosphorylation / drug effects. Rats. Signal Transduction / drug effects. Up-Regulation


74. Schaff Z, Kovalszky I, Lotz G, Kiss A: [Hepatocellular carcinoma--from macroscopy to molecular pathology]. Orv Hetil; 2010 Jun 13;151(24):982-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatocellular carcinoma--from macroscopy to molecular pathology].
  • [Transliterated title] A hepatocellularis carcinoma--a makroszkópiától a molekuláris patológiáig.
  • Hepatocellular carcinoma (HCC) is a tumor with rather bad prognosis.
  • Recent years, however, have seen considerable progress in the diagnostics and treatment of this disease, contributing to better understanding of its molecular pathogenesis.
  • Microscopically the WHO distinguishes trabecular, acinar (pseudoglandular), scirrhous and solid forms.
  • Special histological subtypes are the clear cell, fibrolamellar and mixed hepato-cholangiocellular variants.
  • Certain tumor markers may help the diagnosis, such as alpha-fetoprotein (AFP), glypican-3, survivin, the recently described agrin and claudins, furthermore, the hepatocyte specific antigen (HSA), which confirms the hepatocytic origin of the tumor.
  • In addition to the Barcelona Clinic Liver Cancer (BCLC) staging classification which determines the course of therapy, the molecular classification of HCC is based on key molecular alterations, many of which are observable in all HCC cases, whereas some alterations are only detectable in certain tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / chemistry. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / chemistry. Liver Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20519181.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 47
  •  go-up   go-down


75. Iwasaki T, Ohta M, Shintani Y, Ikeda N: Successful intentional lobectomy for lung cancer after treating contralateral diaphragmatic eventration. Interact Cardiovasc Thorac Surg; 2010 Jun;10(6):1049-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 55-year-old woman had cT1N0M0 lung adenocarcinoma in the right lower lobe and diaphragmatic eventration in the left hemithorax.
  • Pathologically, the tumor was a well-differentiated acinar adenocarcinoma (pT1N0M0 stage IA).
  • [MeSH-major] Adenocarcinoma / surgery. Diaphragmatic Eventration / surgery. Lung / surgery. Lung Neoplasms / surgery. Pneumonectomy. Thoracotomy
  • [MeSH-minor] Cell Differentiation. Female. Humans. Lymph Node Excision. Middle Aged. Neoplasm Staging. Recovery of Function. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20231308.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


76. Stelow EB, Bardales RH, Shami VM, Woon C, Presley A, Mallery S, Lai R, Stanley MW: Cytology of pancreatic acinar cell carcinoma. Diagn Cytopathol; 2006 May;34(5):367-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytology of pancreatic acinar cell carcinoma.
  • Acinar cell carcinoma (ACC) of the pancreas is extremely uncommon and its cytologic features have rarely been described.
  • We describe the cytologic features of cases we have seen, review the literature regarding its cytologic features and discuss the pitfalls that may be encountered and the use of immunohistochemistry for its diagnosis.
  • Original cytologic diagnoses included "acinar cell carcinoma," "pancreatic endocrine tumor," "favor neuroendocrine tumor, low-grade" and "non-diagnostic specimen."
  • The cytologic features included small to moderate-sized loose groups with numerous single cells, prominent acinar formation, little anisonucleosis and prominent nucleoli.
  • The cytologic features showed significant overlap with those of pancreatic endocrine tumors.
  • [MeSH-major] Carcinoma, Acinar Cell / secondary. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Female. Humans. Keratins / analysis. Liver Neoplasms / chemistry. Liver Neoplasms / secondary. Lymph Nodes / pathology. Male. Middle Aged. Pancreas / chemistry. Pancreas / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604543.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


77. Kawano Y, Kitaoka M, Hamada Y, Walker MM, Waxman J, Kypta RM: Regulation of prostate cell growth and morphogenesis by Dickkopf-3. Oncogene; 2006 Oct 19;25(49):6528-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of prostate cell growth and morphogenesis by Dickkopf-3.
  • Ectopic expression of Dkk-3 inhibited colony formation in LNCaP and PC3 prostate cancer cell lines and inducible expression of Dkk-3 reduced LNCaP cell proliferation.
  • Moreover, small interfering RNA-mediated downregulation of Dkk-3 enhanced cell cycle progression in untransformed RWPE-1 prostate epithelial cells.
  • Consistent with this, depletion of Dkk-3 disrupted acinar morphogenesis of RWPE-1 cells in a three-dimensional cell culture model.
  • Our results are consistent with the loss of Dkk-3 expression resulting in impairment of glandular structure and uncontrolled prostate epithelial cell (PrEC) proliferation, both of which are crucial for prostate cancer progression.
  • [MeSH-major] Cell Differentiation. Cell Proliferation. Intercellular Signaling Peptides and Proteins / physiology. Prostate / growth & development
  • [MeSH-minor] Carcinoma / metabolism. Epithelial Cells / metabolism. Gene Expression Regulation, Developmental. Humans. Male. Morphogenesis / physiology. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / metabolism. RNA, Small Interfering / pharmacology. Transfection. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16751809.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DKK3 protein, human; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Small Interfering
  •  go-up   go-down


78. Mansfield A, Tafur A, Smithedajkul P, Corsini M, Quevedo F, Miller R: Mayo Clinic experience with very rare exocrine pancreatic neoplasms. Pancreas; 2010 Oct;39(7):972-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Available evidence suggests that VREP have different risk factors and prognoses from those of adenocarcinoma of the pancreas.
  • METHODS: We reviewed patients from 1975 to 2005 who had VREP and compared them to patients with adenocarcinomas that were matched for TNM, grade, and decade of treatment.
  • The most commonly identified neoplasms were acinar cell carcinoma (n = 15), small cell carcinoma (n = 12), and squamous cell carcinoma (n = 8).
  • There was no difference in the survival of patients with stage 4 disease between cases, 8 months (range, 2.3-21.8 months), and controls, 6.7 months (range, 2.3-10.8 months) (P = 0.17).
  • The overall survival of all patients with VREP was better than matched controls, but no statistical difference was seen between the groups with stage 4 disease.
  • [MeSH-minor] Adult. Aged. Carcinoma, Acinar Cell / mortality. Carcinoma, Small Cell / mortality. Carcinoma, Squamous Cell / mortality. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Rare Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20622706.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Del Vecchio M, Foschini MP, Peterse JL, Eusebi V: Lobular carcinoma of the breast with hybrid myoepithelial and secretory ("myosecretory") cell differentiation. Am J Surg Pathol; 2005 Nov;29(11):1530-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lobular carcinoma of the breast with hybrid myoepithelial and secretory ("myosecretory") cell differentiation.
  • Three cases of lobular carcinoma of the breast showing a complex morphology that included myoepithelial cell differentiation are reported.
  • One case was a pure in situ acinar lesion, while the other 2 cases were in situ and invasive carcinomas.
  • Three different cell types were seen in these tumors: one was the phenotype commonly seen in the garden variety of in situ lobular carcinoma (LCIS) constituted by noncohesive round to ovoid cells with round nuclei and positivity for epithelial membrane antigen (EMA), estrogen receptor (ER), and progesteron receptor (PR).
  • The third type, seen in a minority of cell population of case nos.
  • This type was defined as "hybrid myosecretory cell" to highlight contractile and secretory properties present at the same time.
  • Cells with hybrid features probably indicate that myoepithelial and secretory cells are strictly related and the existence of a stem cell, at least for these cases, is not necessary.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Lobular / pathology. Myoepithelioma / pathology
  • [MeSH-minor] Adult. Cell Differentiation. Female. Humans. Mastectomy. Middle Aged


80. Shigeishi H, Ohta K, Hiraoka M, Fujimoto S, Minami M, Higashikawa K, Kamata N: Expression of TPX2 in salivary gland carcinomas. Oncol Rep; 2009 Feb;21(2):341-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of TPX2 in salivary gland carcinomas.
  • The purpose of this study was to clarify the expression of TPX2 mRNA and correlation between TPX2 and clinicopathological factors in salivary gland carcinomas.
  • The expression of TPX2 mRNA was investigated in 20 human salivary gland carcinomas (8 mucoepidermoid carcinomas, 7 adenoid cystic carcinomas, 5 acinic cell carcinomas) and 6 normal submandibular glands using real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR).
  • The mean expression level of TPX2 mRNA was higher in mucoepidermoid carcinomas (0.53+/-0.51) than in normal submandibular glands (0.047+/-0.029); a significant association was found (Mann-Whitney U test, P=0.0067).
  • The mean expression levels of TPX2 were also higher in acinic cell carcinomas (0.45+/-0.49) and adenoid cystic carcinomas (0.28+/-0.22) than in normal submandibular glands.
  • These results indicate that human TPX2 mRNA is closely linked to increased or abnormal cell proliferation in malignant salivary gland tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / metabolism. Cell Cycle Proteins / biosynthesis. Microtubule-Associated Proteins / biosynthesis. Nuclear Proteins / biosynthesis. Salivary Gland Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19148505.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Extracellular Matrix Proteins; 0 / Microtubule-Associated Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / TPX2 protein, human; 0 / hyaluronan-mediated motility receptor
  •  go-up   go-down


81. Deshpande A, Munshi M: Renal oncocytoma with hyaline globules: cytologic diagnosis by guided fine needle aspiration, a case report. Indian J Pathol Microbiol; 2005 Apr;48(2):230-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal oncocytoma with hyaline globules: cytologic diagnosis by guided fine needle aspiration, a case report.
  • An accurate pre-operative diagnosis by guided fine needle aspiration cytology helps to plan a more conservative surgery.
  • Smears showed polygonal or rounded cells in groups and acinar pattern having a well-defined, granular, eosinophilic cytoplasm, and round regular nuclei displaying very little pleomorphism.
  • Renal oncocytoma has to be distinguished from granular renal cell carcinoma (RCC) and chromophobe cell carcinoma, because of the markedly different prognosis.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / pathology. Kidney Neoplasms / diagnosis. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16758678.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


82. Wang XQ, Li H, Van Putten V, Winn RA, Heasley LE, Nemenoff RA: Oncogenic K-Ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9. Mol Biol Cell; 2009 Feb;20(3):791-800
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncogenic K-Ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9.
  • Expression of oncogenic K-Ras is frequently observed in non-small-cell lung cancer.
  • To examine the biological effects of K-Ras in nontransformed lung epithelial cells, stable transfectants were generated in RL-65 cells, a spontaneously immortalized lung epithelial cell line.
  • Epithelial cells expressing oncogenic K-Ras showed increased proliferation in two- and three-dimensional tissue culture and delayed formation of hollow acinar structures in three-dimensional matrigel cultures.
  • These data indicate that although expression of oncogenic K-Ras does not transform lung epithelial cells, it alters the phenotype of the cells by increasing proliferation and decreasing cell-cell contacts characteristic of epithelial cells.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Nov 25;18(50):7080-90 [10597309.001]
  • [Cites] Dev Cell. 2006 Nov;11(5):601-12 [17084354.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1226-32 [11042196.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] J Biol Chem. 2001 Nov 16;276(46):42737-43 [11559711.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):544-51 [11905709.001]
  • [Cites] Genes Dev. 2002 Aug 15;16(16):2045-57 [12183360.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] J Cell Sci. 2003 Sep 15;116(Pt 18):3687-700 [12890751.001]
  • [Cites] Am J Physiol. 1990 Dec;259(6 Pt 1):L415-25 [2260675.001]
  • [Cites] Genes Dev. 1996 Oct 1;10(19):2462-77 [8843198.001]
  • [Cites] J Biol Chem. 1996 Dec 20;271(51):32491-4 [8955068.001]
  • [Cites] Mol Carcinog. 1996 Dec;17(4):217-23 [8989915.001]
  • [Cites] J Biol Chem. 1997 Jun 6;272(23):14501-4 [9169405.001]
  • [Cites] Mol Biol Cell. 1998 Aug;9(8):2185-200 [9693375.001]
  • [Cites] J Biol Chem. 1998 Aug 21;273(34):22120-7 [9705357.001]
  • [Cites] Oncogene. 2006 Nov 16;25(54):7117-30 [16751808.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11370-80 [17145883.001]
  • [Cites] Genes Dev. 2006 Dec 1;20(23):3199-214 [17158740.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2030-9 [17332331.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):415-28 [17508028.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13672-7 [17690246.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:237-61 [17539752.001]
  • [Cites] Cell. 2008 May 16;133(4):704-15 [18485877.001]
  • [Cites] Oncogene. 1998 Sep 17;17(11 Reviews):1395-413 [9779987.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1412-22 [15608671.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9182-7 [15958533.001]
  • [Cites] J Cell Sci. 2005 Aug 1;118(Pt 15):3371-85 [16079281.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):548-58 [16098727.001]
  • [Cites] Science. 2005 Dec 2;310(5753):1504-10 [16293724.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2116-28 [16489012.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4662-71 [16651417.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22429-33 [16793760.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7057-65 [11156412.001]
  • (PMID = 19037103.001).
  • [ISSN] 1939-4586
  • [Journal-full-title] Molecular biology of the cell
  • [ISO-abbreviation] Mol. Biol. Cell
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA058187; United States / NCI NIH HHS / CA / CA58187; United States / NCI NIH HHS / CA / R01 CA138528; United States / NCI NIH HHS / CA / CA108610; United States / NCI NIH HHS / CA / R01 CA108610; United States / NCI NIH HHS / CA / R01 CA116527; United States / NCI NIH HHS / CA / CA103618; United States / NCI NIH HHS / CA / R01 CA103618
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / Cyclooxygenase Inhibitors; 0 / Kras protein, rat; 0 / beta Catenin; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / Ptgs2 protein, rat; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  • [Other-IDs] NLM/ PMC2633382
  •  go-up   go-down


83. Miliauskas JR, Hunt JL: Primary unilateral multifocal pleomorphic adenoma of the parotid gland: molecular assessment and literature review. Head Neck Pathol; 2008 Dec;2(4):339-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple separate tumors developing in a single salivary gland is rare in previously untreated patients.
  • Tumors that can be multicentric include Warthin tumor, oncocytoma, basal cell adenoma and acinic cell carcinoma.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngorhinootologie. 2007 Jun;86(6):448-50 [17219338.001]
  • [Cites] Lab Invest. 2001 Sep;81(9):1289-97 [11555676.001]
  • [Cites] Ear Nose Throat J. 2002 May;81(5):341-5 [12025006.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Sep;33(6):531-4 [15308250.001]
  • [Cites] Arch Otolaryngol. 1966 Sep;84(3):329-31 [4287765.001]
  • [Cites] Am J Surg. 1969 Nov;118(5):787-9 [4310431.001]
  • [Cites] J Laryngol Otol. 1977 Jul;91(7):629-32 [197179.001]
  • [Cites] Laryngoscope. 1982 Nov;92(11):1265-8 [6292599.001]
  • [Cites] Cancer. 1989 Mar 15;63(6):1219-24 [2917323.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):431-5 [8630948.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Jan;32B(1):3-7 [8729611.001]
  • [Cites] Cancer. 1953 Nov;6(6):1065-133 [13106826.001]
  • [Cites] Ann Otolaryngol. 1954;71(5-6):474-5 [13181211.001]
  • [Cites] Acta Otolaryngol Suppl. 1964;188:SUPPL 191:1-99 [14156485.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):498-503 [10821498.001]
  • (PMID = 20614306.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2807582
  • [Keywords] NOTNLM ; Multifocal / Parotid gland / Pleomorphic adenoma
  •  go-up   go-down


84. Ribeiro HB, Paiva TF Jr, Mamprin GP, Gorzoni ML, Rocha AJ, Lancellotti CL: Carcinomatous encephalitis as clinical presentation of occult lung adenocarcinoma: case report. Arq Neuropsiquiatr; 2007 Sep;65(3B):841-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinomatous encephalitis as clinical presentation of occult lung adenocarcinoma: case report.
  • A magnetic resonance imaging (MRI) with gadolinium, the method of choice, presumes the diagnosis.
  • Previous reports of this unusual form of metastatic disease have described patients with prior diagnosis of pulmonary adenocarcinoma.
  • We present the case of carcinomatous encephalitis in a 76-year-old woman as the primary manifestation of occult pulmonary adenocarcinoma with its clinical, imaging, and anatomopathological findings.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Acinar Cell / secondary. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952293.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


85. Illyés G, Luczay A, Benyó G, Kálmán A, Borka K, Köves K, Rácz K, Tulassay T, Schaff Z: Cushing's syndrome in a child with pancreatic acinar cell carcinoma. Endocr Pathol; 2007;18(2):95-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cushing's syndrome in a child with pancreatic acinar cell carcinoma.
  • A case of pancreatic acinar cell tumor (ACC) is presented in a 10-year-old boy.
  • The tumor manifested clinically with Cushing's syndrome, high serum adrenocorticotropic hormone (ACTH) and cortisol concentrations.
  • Periodic acid Schiff positive cytoplasmic granules, trypsinogen, keratins, alpha-1-antitrypsin, and AFP were identified in the tumor cells.
  • Using immunochemiluminometric assay, a high quantity of ACTH was found in the fresh frozen tumor extract.
  • Combined radiochemotherapy was temporarily effective in reducing the tumor mass and serum AFP.
  • Two years later, the patient died with metastatic disease.
  • [MeSH-major] Carcinoma, Acinar Cell / complications. Cushing Syndrome / etiology. Pancreatic Neoplasms / complications


86. Buchner A, Merrell PW, Carpenter WM: Relative frequency of intra-oral minor salivary gland tumors: a study of 380 cases from northern California and comparison to reports from other parts of the world. J Oral Pathol Med; 2007 Apr;36(4):207-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative frequency of intra-oral minor salivary gland tumors: a study of 380 cases from northern California and comparison to reports from other parts of the world.
  • BACKGROUND: The relative frequency of individual intra-oral minor salivary gland tumors (IMSGT) is not well documented in the literature.
  • Tumors were classified according to the 2005 WHO classification of salivary gland tumors.
  • Of the 380 tumors, 224 (59%) were benign and 156 (41%) were malignant.
  • Of the benign tumors, pleomorphic adenoma (PA) was the most common (39.2%), followed by cystadenoma (6.3%), canalicular adenoma (6.1%), ductal papillomas (4.4%), basal cell adenoma (1.6%), and myoepithelioma (1.3%).
  • Of the malignant tumors, mucoepidermoid carcinoma was the most common (21.8%), followed by polymorphous low-grade adenocarcinoma (7.1%), adenoid cystic carcinoma (6.3%), adenocarcinoma, not otherwise specified (NOS; 2.1%), acinic cell carcinoma (1.6%), clear cell carcinoma, NOS (1.0%), and carcinoma ex PA (0.5%).
  • CONCLUSIONS: Studies related to the relative frequency of individual IMSGTs from different parts of the world are difficult to compare because many studies are outdated, the number of cases is small, the list of tumors is limited, and new entities are not included.
  • To determine the true relative frequency, more studies should be conducted, on a large number of cases from one source, by experienced pathologists in the field of salivary gland tumors.
  • [MeSH-minor] Adenoma, Pleomorphic / epidemiology. Adenoma, Pleomorphic / pathology. Adolescent. Adult. Aged. Aged, 80 and over. California / epidemiology. Carcinoma, Adenoid Cystic / epidemiology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / epidemiology. Carcinoma, Mucoepidermoid / pathology. Child. Cystadenoma / epidemiology. Cystadenoma / pathology. Female. Humans. Male. Middle Aged. Prevalence

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17391298.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


87. Suzuki M, Sakurai H, Seno S, Hoshi J, Ogawa T, Arikata M, Tojima I, Kitanishi T, Tanaka H, Shimizu T: [Endoscopic resection of benign and malignant tumors in the nasal cavity and paranasal sinus]. Nihon Jibiinkoka Gakkai Kaiho; 2005 Jul;108(7):724-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoscopic resection of benign and malignant tumors in the nasal cavity and paranasal sinus].
  • Endoscopic resection of nasal and paranasal sinus tumors is more aesthetic and less invasive than conventional resection, such as Luc's operation and lateral rhinotomy.
  • We clarified the effect of radical endoscopic tumor excision and the control of local bleeding hazardous in endoscopic surgery.
  • Subjects were patients with benign lesions in the nasal cavity, medial wall of the maxillary sinus, ethmoid sinus, and/or sphenoid sinus without concurrent malignant lesions.
  • Although patients selection for malignant tumor excision was based on (1) possible en bloc resection, (2) low-grade malignant tumors, and (3) tumors in the nasal cavity and adjoining paranasal sinus, the final decision was made individual.
  • Subjects were 23 patients with benign tumor (10 inverted papilloma, 9 hemangioma, 2 juvenile angiofibroma, and 2 other tumors) and 4 with malignant tumor (olfactory neuroblastoma, acinic cell carcinoma, squamous cell carcinoma, and chondroid chordoma) in the nasal and paranasal sinus.
  • The tumor was resected en bloc except for patients with inverted papilloma (2 cases) and chondroid chordoma.
  • Recurrence in benign tumors was zero during a mean observation of 21 months.
  • Endoscopic removal of malignant lesions remains controversial because of the small number of patients and short postoperative observation.

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16107047.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


88. Darling MR, Jackson-Boeters L, Daley TD, Diamandis EP: Human kallikrein 13 expression in salivary gland tumors. Int J Biol Markers; 2006 Apr-Jun;21(2):106-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human kallikrein 13 expression in salivary gland tumors.
  • Petraki et al have previously described presence of hK13 in salivary gland tissue, localized to duct epithelia and some acinar cells.
  • The aim of this study was to determine whether hK13 is expressed in salivary gland tissues and salivary gland tumors (both benign and malignant), in order to compare normal with tumor tissues.
  • Pleomorphic adenomas (PA), adenoid cystic carcinomas (ACC), polymorphous low grade adenocarcinomas (PLGA), acinic cell carcinomas (ACI), mucoepidermoid carcinomas (MEC) and adenocarcinomas not otherwise specified (ANOS) of both minor and major salivary glands were examined.
  • The results of this study indicate that most salivary gland tumors show high levels of expression of hK13.
  • Ductal cells and cells lining duct-like structures showed a higher intensity of staining than non-ductal cells in most tumors.
  • Tumors which exhibited only non-ductal cells also exhibited cytoplasmic staining.
  • In conclusion, we demonstrate the high expression of hK13 in several common salivary gland tumors.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Adenoid Cystic / metabolism. Gene Expression Regulation, Neoplastic. Kallikreins / biosynthesis. Mouth Mucosa / metabolism. Salivary Gland Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenoma, Pleomorphic / metabolism. Carcinoma, Mucoepidermoid / metabolism. Humans. Immunohistochemistry. Prognosis. Salivary Glands / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16847813.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.- / KLK13 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


89. Adley BP, Yang XJ: Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review. Anal Quant Cytol Histol; 2006 Feb;28(1):1-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review.
  • Alpha-methylacyl coenzyme A racemase (AMACR) is a recently discovered enzyme protein that has been shown to be increased at both the mRNA and protein levels in prostatic adenocarcinoma as compared with normal prostatic tissues.
  • Since its discovery, AMACR has gained wide acceptance for use in the diagnosis of prostatic adenocarcinoma in conjunction with morphology and immunohistochemical staining for basal cell markers.
  • This review focuses on AMACR expression in prostate cancer and its morphologic variants, high grade prostatic intraepithelial neoplasia, adenosis and benign conditions of the prostate.
  • In addition, we discuss AMACR expression in other tumors.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566275.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  • [Number-of-references] 63
  •  go-up   go-down


90. National Toxicology Program: NTP technical report on the toxicology and carcinogenesis studies of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (CAS No. 1746-01-6) in female Harlan Sprague-Dawley rats (Gavage Studies). Natl Toxicol Program Tech Rep Ser; 2006 Apr;(521):4-232
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HEPATIC CELL PROLIFERATION DATA: To evaluate hepatocyte replication, analysis of labeling of replicating hepatocytes with 5-bromo-2'-deoxyuridine was conducted at the 14-, 31-, and 53-week interim evaluations.
  • At 2 years, there was a significant increase in toxic hepatopathy characterized by increased incidences of numerous nonneoplastic liver lesions including hepatocyte hypertrophy, multinucleated hepatocytes, altered hepatocellular foci, inflammation, pigmentation, diffuse fatty change, necrosis, portal fibrosis, oval cell hyperplasia, bile duct hyperplasia, bile duct cysts, cholangiofibrosis, and nodular hyperplasia At 2 years, the incidence of hepatocellular adenoma was significantly increased in the 100 ng/kg core study group.
  • The incidence of gingival squamous cell carcinoma of the oral mucosa was significantly increased in the 100 ng/kg core study group at 2 years and was accompanied by an increased incidence of gingival squamous hyperplasia.
  • At 2 years, the incidence of squamous cell carcinoma of the uterus in the 46 ng/kg group was significantly increased, and there were two squamous cell carcinomas in the 100 ng/kg stop-exposure group.
  • At 2 years, one acinar adenoma and two acinar cell carcinomas of the pancreas were seen in the 100 ng/kg core study group; one acinar carcinoma was seen in the 100 ng/kg stop-exposure group.
  • The incidences of acinar cell adenoma or carcinoma (combined) exceeded the historical vehicle control range.
  • Nonneoplastic effects in the lung included acinar cytoplasmic vacuolization, chronic active inflammation, acinar atrophy, and arterial chronic active inflammation. (ABSTRACT TRUNCATED)

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835633.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; DO80M48B6O / Tetrachlorodibenzodioxin
  •  go-up   go-down


91. Stelow EB, Shaco-Levy R, Bao F, Garcia J, Klimstra DS: Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma. Am J Surg Pathol; 2010 Apr;34(4):510-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma.
  • BACKGROUND: Pancreatic acinar cell carcinomas (ACCs) are clinically and pathologically distinct from pancreatic ductal adenocarcinomas (PDAs).
  • At last follow-up, 7 patients died of disease and 2 others had recurrences.
  • Tumors measured between 2 and 5.5 cm and were ill-defined, nodular, and multilobulated.
  • All cases showed significant evidence of both acinar and ductal differentiation, estimated to be at least 25% of the neoplastic cells, and 3 cases in addition had endocrine differentiation in more than 25% of cells.
  • Five cases were predominately acinar with intracellular and sometimes extracellular mucin ("mucinous acinar cell carcinoma" pattern).
  • Six cases seemed more mixed with areas recapitulating typical PDAs whereas the other portions of the tumors seemed akin to typical acinar cell carcinomas ("combined acinar and ductal" pattern).
  • CONCLUSION: Despite the early embryologic divergence of acinar and ductal cell lineages, rare pancreatic tumors have both acinar and ductal differentiation, usually predominantly the former.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Carcinoma, Islet Cell / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Combined Modality Therapy. DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Mucins / metabolism. Mutation. Neoplasms, Multiple Primary. New York / epidemiology. Pancreatectomy. Proto-Oncogene Proteins / genetics. Survival Rate. Virginia / epidemiology. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20182344.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Mucins; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


92. Hashimoto M, Miki K, Kokudo N, Beck Y, Makuuchi M: A long-term survivor of metastatic acinar cell carcinoma. Pancreas; 2007 Mar;34(2):271-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-term survivor of metastatic acinar cell carcinoma.
  • [MeSH-major] Carcinoma, Acinar Cell / secondary. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17312470.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


93. Schwentner I, Obrist P, Thumfart W, Sprinzl G: Distant metastasis of parotid gland tumors. Acta Otolaryngol; 2006 Apr;126(4):340-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distant metastasis of parotid gland tumors.
  • Patients with malignant salivary gland tumors should have an X-ray or CT scan of the chest at their initial assessment to exclude the possibility of distant metastasis.
  • The likelihood of developing distant metastasis is associated with high-grade tumors, such as adenoid cystic carcinoma, salivary duct carcinoma, high-grade mucoepidermoid carcinoma and tumors located in the submandibular gland, posterior tongue and pharyngeal tumors.
  • A lower risk of developing distant metastasis is known for all other histological entities of salivary gland tumors.
  • Nevertheless all patients who have a histologically confirmed malignant salivary gland tumor should have lifelong follow-up.
  • [MeSH-minor] Aged. Bone Neoplasms / secondary. Brain Neoplasms / secondary. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / secondary. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / secondary. Carcinoma, Mucoepidermoid / pathology. Carcinoma, Mucoepidermoid / secondary. Fatal Outcome. Humans. Immunohistochemistry. Incidence. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Parotid Gland / pathology. Parotid Gland / surgery. Salivary Ducts / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608783.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 32
  •  go-up   go-down


94. Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, Davies SE, Olive KP, Tuveson DA, Venkitaraman AR: Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell; 2010 Nov 16;18(5):499-509
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We find in a murine model of familial pancreatic cancer that germline heterozygosity for a pathogenic Brca2 truncation suffices to promote pancreatic ductal adenocarcinomas (PDACs) driven by Kras(G12D), irrespective of Trp53 status.
  • Unexpectedly, tumor cells retain a functional Brca2 allele.
  • Three tumors from these patients displaying LOH were acinar carcinomas, which also developed only in mice with biallelic Brca2 inactivation.
  • We suggest a revised model for tumor suppression by BRCA2 with implications for the therapeutic strategy targeting BRCA2 mutant cancer cells.
  • [MeSH-major] BRCA2 Protein / genetics. Carcinoma, Pancreatic Ductal / genetics. Disease Models, Animal. Genes, BRCA2. Germ-Line Mutation. Heterozygote. Pancreatic Neoplasms / genetics. Proto-Oncogene Proteins p21(ras) / genetics
  • [MeSH-minor] Alleles. Animals. Cell Line, Tumor. Codon, Nonsense. Gene Silencing. Loss of Heterozygosity. Mice. Mice, 129 Strain. Mice, Inbred C57BL. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21056012.001).
  • [ISSN] 1878-3686
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105359877; United Kingdom / Medical Research Council / / ; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / / G9900064; United Kingdom / Medical Research Council / / G0600332; United Kingdom / Medical Research Council / / G0700651
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRCA2 Protein; 0 / Codon, Nonsense; 0 / Tumor Suppressor Protein p53; EC 3.6.5.2 / Kras2 protein, mouse; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


95. Ikeda S, Fujimori M, Shibata S, Okajima M, Ishizaki Y, Kurihara T, Miyata Y, Iseki M, Shimizu Y, Tokumoto N, Ozaki S, Asahara T: Combined immunohistochemistry of beta-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer. BMC Cancer; 2006;6:31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined immunohistochemistry of beta-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer.
  • However, often, the discriminating diagnosis of primary lung acinar adenocarcinoma and lung metastasis of colorectal cancer based on morphological and pathological findings is difficult.
  • The purpose of this study was to evaluate the clinical usefulness of immunohistochemistry of beta-catenin, cytokeratin (CK) 7, and CK20 for the discriminating diagnosis of lung cancer.
  • METHODS: We performed immunohistochemistry of beta-catenin, CK7, and CK20 in 19 lung metastasis of colorectal cancer samples, 10 corresponding primary colorectal cancer samples and 11 primary lung acinar adenocarcinoma samples and compared the levels of accuracy of the discriminating diagnosis by using antibodies against these antigens.
  • RESULTS: Positive staining of beta-catenin was observed in all the lung metastasis of colorectal cancer samples as well as in the primary colorectal cancer samples but in none of the primary lung acinar adenocarcinoma samples.
  • Positive staining of CK7 was observed in 90.9% of the primary lung acinar adenocarcinoma samples and in 5.3% of the lung metastasis of colorectal cancer samples, but in none of the primary colorectal cancer samples.
  • Positive staining of CK20 was observed in all the primary colorectal cancer samples and in 84.2% of the lung metastasis of colorectal cancer samples, but in none of the primary lung acinar adenocarcinoma samples.
  • CONCLUSION: Combined immunohistochemistry of beta-catenin, CK7, and CK20 is useful for making a discriminating diagnosis between lung metastasis of colorectal cancer and primary lung acinar adenocarcinoma.
  • This method will enable accurate diagnosis of a lung tumor and will be useful for selecting appropriate therapeutic strategies, including chemotherapeutic agents and operation methods.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Gene Expression Profiling. Humans. Immunohistochemistry. Keratin-20. Keratin-7. Keratins / analysis. Retrospective Studies. Sensitivity and Specificity. beta Catenin / analysis


96. Rubello D, Nanni C, Castellucci P, Rampin L, Farsad M, Franchi R, Mariani G, Menaldo G, Fanti S: Does 18F-FDG PET/CT play a role in the differential diagnosis of parotid masses. Panminerva Med; 2005 Sep;47(3):187-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does 18F-FDG PET/CT play a role in the differential diagnosis of parotid masses.
  • METHODS: The potential role of 18F-FDG PET/CT in distinguishing benign from malignant parotid masses in 14 consecutive patients was investigated.
  • For To interpreting FDG PET findings, the right to left parotid (R/L) SUV max ratio was calculated in a group of 54 patients without evidence of parotideal disease (mean+/-SD = 1+/-0.2; range = 0.8-1.2); considering the R/L SUV max ratio, focal or diffuse uptakes <0.8 or >1.2 were considered as potentially pathological.
  • At FDG PET/CT, 9 false positive cases were found (8 Warthin's tumours, 1 pleomorphic adenoma), 1 false negative (acinar cell carcinoma), 4 true negative (1 Warthin's tumour, 1 pleomorphic adenoma, 1 lymph epithelial cyst, 1 parotid inflammation) whereas there was no case of true positive.
  • CONCLUSIONS: In agreement with other preliminary reports in which the FDG PET without CT fusion imaging was used, in our experience 18F-FDG PET/CT did not prove to play a significant role in differential diagnosis (benign vs malignant) of parotid masses.
  • [MeSH-major] Fluorodeoxyglucose F18. Parotid Neoplasms / diagnosis. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462726.001).
  • [ISSN] 0031-0808
  • [Journal-full-title] Panminerva medica
  • [ISO-abbreviation] Panminerva Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


97. Yoon WJ, Lee JK, Lee KH, Ryu JK, Kim YT, Yoon YB: Cystic neoplasms of the exocrine pancreas: an update of a nationwide survey in Korea. Pancreas; 2008 Oct;37(3):254-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A total of 1064 pathologically confirmed PCNs, which consisted of the following diagnoses, were collected: intraductal papillary mucinous neoplasm (IPMN), 436; mucinous cystic neoplasm (MCN), 268; solid pseudopapillary neoplasm (SPN), 195; serous cystic neoplasm (SCN), 162; acinar cell cystic neoplasm 2; and mature teratoma, 1.
  • No malignant SCNs were diagnosed.
  • In IPMNs, advanced age was associated with malignancy, suggesting an adenoma-carcinoma sequence.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18815545.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Reske SN: [PET and PET-CT of malignant tumors of the exocrine pancreas]. Radiologe; 2009 Feb;49(2):131-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [PET and PET-CT of malignant tumors of the exocrine pancreas].
  • Adenocarcinomas of the pancreas represent the majority (>95%) of all malignant pancreatic tumors.
  • They are formed from malignant degeneration of the exocrine part of the pancreas.
  • Cystic acinar tumors are much rarer and originate from secretion-producing parenchymal cells of the pancreas.
  • Endocrine tumors of the pancreas will not be dealt with in this context.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Carcinoma, Acinar Cell / diagnostic imaging. Carcinoma, Pancreatic Ductal / diagnostic imaging. Image Processing, Computer-Assisted. Pancreatic Neoplasms / diagnostic imaging. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis / diagnostic imaging. Lymphatic Metastasis / pathology. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Staging. Pancreas / diagnostic imaging. Pancreas / pathology. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2006 Nov-Dec;40(10 ):923-9 [17063113.001]
  • [Cites] J Nucl Med. 2008 Sep;49(9):1437-44 [18703612.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] Eur J Nucl Med. 1998 Mar;25(3):259-64 [9580859.001]
  • [Cites] J Nucl Med. 1999 Feb;40(2):250-5 [10025831.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Sep;31(9):1352 [15197505.001]
  • [Cites] J Gastroenterol. 2003;38(12 ):1189-93 [14714260.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):932-7; discussion 937-9 [18043094.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):891-9 [15516961.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):399-404 [15549297.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):475-6 [16012303.001]
  • [Cites] J Nucl Med. 2007 Jan;48 Suppl 1:78S-88S [17204723.001]
  • [Cites] Gastroenterol Clin Biol. 2002 Oct;26(10 ):888-92 [12434099.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1775-85 [18481063.001]
  • [Cites] Recent Results Cancer Res. 2008;177:15-26 [18084943.001]
  • [Cites] Nuklearmedizin. 2005;44 Suppl 1:S18-23 [16395974.001]
  • [Cites] Clin Nucl Med. 2002 Mar;27(3):197-201 [11852308.001]
  • [Cites] Scand J Surg. 2004;93(3):191-7 [15544073.001]
  • [Cites] Clin Positron Imaging. 1999 May;2(3):131-136 [14516536.001]
  • [Cites] J Nucl Med. 2008 Sep;49(9):1408-13 [18703604.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):425-34 [16766262.001]
  • [Cites] J Gastrointest Surg. 2006 Dec;10 (10 ):1354-60 [17175454.001]
  • [Cites] J Nucl Med. 2001 May;42(5 Suppl):1S-93S [11483694.001]
  • [Cites] J Gastroenterol. 2004 Jan;39(1):50-5 [14767734.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):287-93 [10917540.001]
  • [Cites] Dig Surg. 2005;22(1-2):55-61; discussion 62 [15838173.001]
  • [Cites] Ann Nucl Med. 2001 Jun;15(3):217-24 [11545191.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:24S-42S [18523064.001]
  • [Cites] Pancreas. 2005 Aug;31(2):192-4 [16025008.001]
  • [Cites] Pancreas. 2000 Mar;20(2):109-16 [10707924.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):235-43 [16041214.001]
  • [Cites] Pancreatology. 2005;5(6):553-61 [16113592.001]
  • [Cites] Eur J Nucl Med. 2001 Nov;28(11):1707-23 [11702115.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):239-46 [15972430.001]
  • [Cites] J Nucl Med. 2008 Mar;49(3):480-508 [18287273.001]
  • [Cites] Pancreatology. 2005;5(2-3):266-72 [15855825.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19219476.001).
  • [ISSN] 1432-2102
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 43
  •  go-up   go-down


99. De La O JP, Emerson LL, Goodman JL, Froebe SC, Illum BE, Curtis AB, Murtaugh LC: Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci U S A; 2008 Dec 2;105(48):18907-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia.
  • Efforts to model pancreatic cancer in mice have focused on mimicking genetic changes found in the human disease, particularly the activating KRAS mutations that occur in pancreatic tumors and their putative precursors, pancreatic intraepithelial neoplasia (PanIN).
  • The basis for this selective response is unknown, and it is similarly unknown what cell types in the mature pancreas actually contribute to PanINs.
  • We hypothesize that Notch, which inhibits differentiation in the embryonic pancreas, contributes to PanIN formation by abrogating the normal differentiation program of tumor-initiating cells.
  • Furthermore, we find that Kras activation in mature acinar cells induces PanIN lesions identical to those seen upon ubiquitous Kras activation, and that Notch promotes both initiation and dysplastic progression of these acinar-derived PanINs, albeit short of invasive adenocarcinoma.
  • At the cellular level, Notch/Kras coactivation promotes rapid reprogramming of acinar cells to a duct-like phenotype, providing an explanation for how a characteristically ductal tumor can arise from nonductal acinar cells.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Development. 2002 May;129(10):2447-57 [11973276.001]
  • [Cites] Nat Med. 2002 Sep;8(9):979-86 [12185362.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2005-9 [12727809.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2016-9 [12727811.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):565-76 [12842085.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):111-20 [12957286.001]
  • [Cites] Nucleic Acids Res. 2003 Dec 15;31(24):e154 [14654707.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14920-5 [14657333.001]
  • [Cites] Dev Dyn. 2004 Jan;229(1):176-200 [14699589.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Pancreas. 2004 Jan;28(1):58-64 [14707731.001]
  • [Cites] Methods Enzymol. 1987;152:219-27 [2443794.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):728-41 [15765408.001]
  • [Cites] Development. 2005 Aug;132(16):3767-76 [16020518.001]
  • [Cites] Genes Dev. 2005 Aug 15;19(16):1825-39 [16103211.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):185-95 [16169464.001]
  • [Cites] Development. 2005 Nov;132(21):4663-74 [16192304.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):95-106 [16397221.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):242-7 [16397237.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4437-42 [17360542.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):263-73 [17591971.001]
  • [Cites] Gastroenterology. 2007 Dec;133(6):1999-2009 [18054571.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):544-55 [18242220.001]
  • [Cites] Annu Rev Pathol. 2008;3:157-88 [18039136.001]
  • (PMID = 19028876.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21-CA123066; United States / NCI NIH HHS / CA / P30-CA042014; United States / NICHD NIH HHS / HD / 5T32-HD07491; United States / NCI NIH HHS / CA / CA123066-02; United States / NCI NIH HHS / CA / R21 CA123066; United States / NCI NIH HHS / CA / R21 CA123066-02; United States / NICHD NIH HHS / HD / T32 HD007491; United States / NCI NIH HHS / CA / P30 CA042014
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Receptors, Notch; 094ZI81Y45 / Tamoxifen; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


100. Tavernier L, Godon A, Algros MP, Rainfaing E, Chobaut JC: [Acinic cell carcinoma in an ectopic salivary gland]. Rev Laryngol Otol Rhinol (Bord); 2010;131(4-5):299-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinic cell carcinoma in an ectopic salivary gland].
  • [Transliterated title] Carcinome à cellules acineuses d'une glande salivaire ectopique.
  • On the occasion of the coverage of a cervical tumefaction in a child, which led to the diagnosis of acinic cell carcinoma of ectopic salivary gland, the authors conducted a literature review of this tumour.
  • This one remains empirical and discussed on a case-by-case basis for a malignant tumour that is exceptional in this location and at that age.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Choristoma / pathology. Mandibular Neoplasms / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21866744.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down






Advertisement